



Azole resistance in a *Candida albicans* mutant lacking the ABC transporter *CDR6/ROA1* depends on TOR signaling

Received for publication, July 16, 2017, and in revised form, November 17, 2017. Published, Papers in Press, November 20, 2017, DOI 10.1074/jbc.M117.807032

Nitesh Kumar Khandelwal^{a,b}, Neeraj Chauhan^c, Parijat Sarkar^d, Brooke D. Esquivel^e, Paola Coccetti^{f,g}, Ashutosh Singh^{a,h}, Alix T. Costeⁱ, Meghna Gupta^{aj}, Dominique Sanglard^j, Theodore C. White^e, Murielle Chauvel^k, Christophe d'Enfert^k, Amitabha Chattopadhyay^d, Naseem A. Gaur^b, Alok Kumar Mondal^a, and Rajendra Prasad^{a,1}

From the ^aSchool of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India, ^cDepartment of Microbiology, Biochemistry, and Molecular Genetics, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey 07103, the ^dCSIR-Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad 500007, India, the ^eSchool of Biological Sciences, Cell Biology, and Biophysics, University of Missouri, Kansas City, Missouri 64110, the ^fDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy, ^gSYSBIO, Centre of Systems Biology, 20126 Milan, Italy, the ^hDepartment of Biochemistry, Lucknow University, Lucknow 226024, Uttar Pradesh, India, the ⁱInstitute of Microbiology, University of Lausanne and University Hospital Center, Rue du Bugnon 48, Lausanne, CH-1011, Switzerland, the ^jDepartment of Biochemistry and Biophysics, University of California, San Francisco, California 94158, the ^kDépartement Génomes et Génétique, Unité Biologie et Pathogénicité Fongiques, Institut Pasteur, INRA, 75015 Paris, France, the ^bInternational Centre for Genetic Engineering and Biotechnology, New Delhi 110067, India, and the ¹Amity Institute of Integrative Sciences and Health, Amity University Haryana, Amity Education Valley Gurgaon-122413, India

Edited by Henrik G. Dohlman

ATP-binding cassette (ABC) transporters help export various substrates across the cell membrane and significantly contribute to drug resistance. However, a recent study reported an unusual case in which the loss of an ABC transporter in *Candida albicans*, orf19.4531 (previously named ROA1), increases resistance against antifungal azoles, which was attributed to an altered membrane potential in the mutant strain. To obtain further mechanistic insights into this phenomenon, here we confirmed that the plasma membrane-localized transporter (renamed *CDR6/ROA1* for consistency with *C. albicans* nomenclature) could efflux xenobiotics such as berberine, rhodamine 123, and paraquat. Moreover, a *CDR6/ROA1* null mutant, NKKY101, displayed increased susceptibility to these xenobiotics. Interestingly, fluorescence recovery after photobleaching (FRAP) results indicated that NKKY101 mutant cells exhibited increased plasma membrane rigidity, resulting in reduced azole accumulation and contributing to azole resistance. Transcriptional profiling revealed that ribosome biogenesis genes were significantly up-regulated in the NKKY101 mutant. As ribosome biogenesis is a well-known downstream phenomenon of target of rapamycin (TOR1) signaling, we suspected a link

between ribosome biogenesis and TOR1 signaling in NKKY101. Therefore, we grew NKKY101 cells on rapamycin and observed TOR1 hyperactivation, which leads to Hsp90-dependent calcineurin stabilization and thereby increased azole resistance. This *in vitro* finding was supported by *in vivo* data from a mouse model of systemic infection in which NKKY101 cells led to higher fungal load after fluconazole challenge than wild-type cells. Taken together, our study uncovers a mechanism of azole resistance in *C. albicans*, involving increased membrane rigidity and TOR signaling.

Candida albicans is the most common human fungal pathogen; causes vaginal, oral and systemic diseases; and contributes to 9–12% of all hospital-acquired infections, with mortality rates approaching 50% (1, 2). Azoles, polyenes, and echinocandins are three major categories of antifungals used to combat invasive fungal infections (3). However, prolonged use of antifungals increases the frequency of the generation of multidrug resistance (MDR)² strains, which show resistance to more than one class of drugs. Target alteration and the overexpression of its gene products are the most common strategies accounting for MDR phenomena in *Candida* species (3, 4). Among the various mechanisms of MDR, enhanced drug expulsion by MDR strains of *Candida* species represents a prominent strat-

This work was supported, in part, by the Department of Biotechnology, Ministry of Science and Technology, Government of India, Grants BT/01/CEIB/10/III/02, BT/PR7392/MED/29/652/2012, and BT/PR14879/BRB10/885/2010 (to R.P.). Research in the laboratory of N.C. was supported by National Institutes of Health Grant R01AI124499. The research work in the laboratory of A. K. M. was supported by a DST PURSE grant. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The microarrays used in the present study along with complete raw transcriptome data can be accessed from the NCBI Gene Expression Omnibus database under accession number GSE70340.

This article contains Figs. S1–S5 and Tables S1–S4.

¹ To whom correspondence should be addressed: Amity Institute of Integrative Sciences and Health, Amity University Haryana, Amity Education Valley Gurgaon-122413, India. E-mail: rp47jnu@gmail.com.

² The abbreviations used are: MDR, multidrug resistance; ABC, ATP-binding cassette; TOR, target of rapamycin; PM, plasma membrane; BER, berberine; R123, rhodamine 123; PQ, paraquat; *CDR6*, *Candida* drug-resistant 6; TMA-DPH, trimethylaminodiphenyl-1,3,5-hexatriene; CR, congo red; FLC, fluconazole; ITR, itraconazole; MCZ, miconazole; KTC, ketoconazole; FRAP, fluorescence recovery after photobleaching; PGL, phosphoglyceride; PE, phosphatidylethanolamine; SPT, serine palmitoyltransferase; CGD, *Candida* Genome Database; di-8-ANEPPS, 4-(2-(6-dioctylamino)-2-naphthalenyl)ethenyl)-1-(3-sulfopropyl)-inner salt; ESI, electrospray ionization; ANM, anisomycin; CHX, cycloheximide; IPC, inositol phosphorylceramide; MIPC, mannosylinositol phosphorylceramide; qRT-PCR, quantitative RT-PCR.

egy. Several studies report low levels of drug accumulation in *C. albicans* drug-resistant clinical isolates. This occurs predominantly due to overexpression of plasma membrane (PM)-localized drug-efflux transporter proteins Cdr1 and Cdr2 of the ATP-binding cassette (ABC) superfamily and Mdr1 of the major facilitator superfamily (5–7).

Apart from enhanced efflux of incoming drugs, which impacts drug susceptibility, the influx of drugs across the PM is also considered to play an important part in the development of drug tolerance. The PM acts as a partition between the extracellular and intracellular environment, and previous studies have shown that alterations in the physical state of the PM could impact intracellular drug accumulation and susceptibility of *C. albicans* cells to azoles (8–10). Interestingly, in yeast, the PM tension activates *TORC2* (target of rapamycin complex 2), which promotes sphingolipid biosynthesis (11). Sphingolipids are important constituents of the detergent-insoluble microdomain of the PM known as lipid rafts, which play an important role as a platform for various signaling mechanisms (12–14). In *C. albicans*, the PM-bound transporter Cdr1 has been shown to be specifically localized within the raft region (15), and any imbalance in raft lipid constituents, such as sphingolipids or ergosterol, results in altered drug susceptibility (16). The occurrence of some of the transporter proteins in raft domains emphasizes their additional role in cell signaling.

In fungi, Hsp90 and calcineurin are two important regulators of cellular response to combat drug-induced stress. Hsp90 acts on various downstream effectors and is required for stability of calcineurin (17). In *Saccharomyces cerevisiae*, Tor1 (target of rapamycin 1) affects the Hsp90 activity in a positive manner by suppressing the expression of Kns1 kinase which phosphorylates Ckb1 (a regulatory subunit of CK2 kinase) and modulates its function (18, 19). CK2 kinase phosphorylates Hsp90 and represses its activity in *S. cerevisiae* and *C. albicans* (20, 21). A recent study has shown that inhibition of Tor1 leads to inhibition of Hsp90 activity, resulting in hypersensitivity to azoles in *S. cerevisiae* and *C. albicans* (22). Thus, hyperactivation of TOR signaling can be an important mechanism used by *C. albicans* to bypass azole toxicity.

The present study deals with a poorly characterized ORF (orf19.4531) of *C. albicans* belonging to the PDR subfamily, which has earlier been observed to be up-regulated in a number of drug-resistant clinical isolates (23, 24). A recent report by Jiang *et al.* (25), which appeared during the course of the present study, suggested that this orf19.4531-encoded protein is localized on a punctuated compartment adjacent to the vacuolar membrane and that its absence results in selective resistance to azoles, and these authors designated it as ROA1 (regulator of azole sensitivity). However, the study could not provide any mechanistic insight into this surprising phenotype.

We demonstrate that orf19.4531 actually codes for a PM-localized protein, which could efflux antifungal berberine (BER), the fluorescent dye rhodamine 123 (R123), and the herbicide paraquat (PQ). The first member of the ABC superfamily characterized in *C. albicans* was designated *CDR1* (*Candida* drug-resistant 1). The other members of the PDR subfamily, *CDR2*, *CDR3*, *CDR4*, and *CDR5/CDR11*, are partially characterized (26, 27). Considering the fact that orf19.4531 is a member of the

PDR subfamily and we show that it plays a role in transport of and resistance to various xenobiotics, we designated it as *CDR6* (*Candida* drug-resistant 6). However, because orf19.4531 is designated as *ROA1* in the *Candida* Genome Database (CGD), we refer it as *CDR6/ROA1*. Interestingly, we observed that Cdr6/Roa1, in addition to being a PM-localized exporter of selected compounds, also impacts lipid homeostasis and the physical state of the PM, resulting in reduced accumulation of azoles in the cell. The decreased intracellular azole concentration results in enhanced resistance to azoles. The increased resistance to azoles could be well-demonstrated *in vitro* as well as in an *in vivo* mouse model. In addition, we observed that the TOR signaling was elicited in the *CDR6/ROA1* null mutant NKKY101 and led to azole resistance by stabilizing calcineurin via activation of Hsp90. This cascade induces ribosome biogenesis and suppresses sphingolipid biosynthesis. Taken together, we uncovered in *C. albicans* the impact of Cdr6/Roa1 on drug resistance, transport, and cell signaling.

Results

Topology prediction by the software TOPOCONS suggested Cdr6/Roa1 to be similar to Cdr1 and Cdr2, both of which possess two transmembrane domains, each composed of six transmembrane helices, which are preceded by two well-conserved nucleotide-binding domains (Fig. 1A, *NBD1* and *NBD2*). However, the phylogenetic analysis of Cdr6 together with all members of the PDR subfamily from *C. albicans* and *S. cerevisiae* showed that Cdr6 stands out as being in a distinct cluster (Fig. S1).

Cdr6 localizes to the plasma membrane

The bioinformatics analysis using the Wolf PSORT (<http://www.genscript.com/wolf-psort.html>)³ and CELLO version 2.5 (<http://cello.life.nctu.edu.tw/>)³ tools predicted that the *C. albicans* *CDR6*-encoding protein could be a PM-localized transporter. To validate this prediction, we cloned the orf19.4531 as a GFP-tagged protein (as described under “Experimental procedures”) in the WT *C. albicans* strain SC5314 at the *RPS1* locus. The resulting strain, expressing N-terminal GFP-tagged Cdr6/Roa1 under the control of the pTDH3 promoter, was designated CA-*CDR6*. The expression and localization of the recombinant Cdr6/Roa1-GFP protein in the CA-*CDR6* strain were confirmed by confocal microscopy, where green fluorescence of the GFP-tagged Cdr6/Roa1 distinctly showed a rimmed appearance on the PM (Fig. 1B). To verify the localization on the PM, trimethylaminodiphenyl-1,3,5-hexatriene (TMA-DPH) was used, which stains the PM specifically (28). As depicted in Fig. 1B in the merge channel, Cdr6/Roa1-GFP overlapped with that of the TMA-DPH stain, indicating the PM localization of Cdr6/Roa1-GFP. Cdr6/Roa1-GFP localization at the PM was further confirmed by Western blotting of the PM fraction using anti-GFP monoclonal antibody (Fig. 1C). Pma1 was used as a control for the PM fraction and loading. It is pertinent to mention that orf19.4531 (designated here as *CDR6/ROA1*) was earlier designated as *ROA1* (regulator of

³ Please note that the JBC is not responsible for the long-term archiving and maintenance of this site or any other third party hosted site.

Cdr6/Roa1, a plasma membrane ABC transporter of C. albicans




Figure 1. Localization of *Cdr6/Roa1* transporter in *C. albicans* and its role in drug resistance. *A*, topology prediction of *Cdr6/Roa1* protein by TOPCONS software and pictorial representation showing typical domain arrangement of PDR subfamily with conserved nucleotide-binding domain (NBD). *B*, fluorescence imaging by confocal microscopy showing PM localization of *Cdr6/Roa1*-GFP with corresponding differential interference contrast (DIC) images, TMA-DPH (PM-specific stain) staining, and merged images. CA-CDR6 cells expressing *Cdr6/Roa1*-GFP were grown until midlog phase in YEPD medium and labeled with TMA-DPH (1.0 μM) for 10 min at 25 $^{\circ}\text{C}$ in the dark. Cells were washed with PBS buffer and imaged using the confocal microscope. Scale bar, 10 μm . *C*, immunoblot showing expression of *Cdr6/Roa1*-GFP protein. PMs were isolated using the sucrose gradient method, and equal amounts of proteins (80 μg) were resolved by SDS-PAGE (8% gel) and then probed with anti-GFP antibody. After probing, the membrane was striped and reprobed with anti-Pma1p polyclonal antibody. Pma1 is used as a control for the PM fraction and for loading. *D*, a comparison of susceptibilities by spot dilution assays between WT and *CDR6/ROA1* null strain NKKY101. A 5-fold serial dilution of each strain was spotted onto PQ, BER, R123, FLC, ITR, KTC, and MCZ at the indicated concentrations in YEPD agar plates and grown for 48 h at 30 $^{\circ}\text{C}$.

azole sensitivity 1) and shown to be localized in small punctuated compartments adjacent to the vacuolar membrane (25).

Next, we further confirmed the localization of Cdr6/Roa1 by expressing it in a heterologous overexpression system, the AD1–8U[−] strain of *S. cerevisiae*, which has been widely used to express *C. albicans* and other yeast ABC transporter proteins (29–31). In the same manner, we cloned *CDR6/ROA1* ORF in pABC3-GFP vector and integrated at the PDR5 locus in the AD1–8U[−] strain. Our confocal microscopy data for GFP-tagged Cdr6/Roa1 and Western blot analysis also confirmed its localization to the PM (data not shown).

Cells lacking *CDR6/ROA1* display altered susceptibility to selected xenobiotics

A homozygous null of *CDR6/ROA1* was constructed, where both of the alleles of diploid *C. albicans* WT strain SC5314 were deleted using a targeted gene deletion strategy (32). The deletion was confirmed by Southern blotting (data not shown). The resulting *CDR6/ROA1* homozygous null strain was designated NKKY101 and subjected to extensive phenotypic analysis. The growth analysis under a variety of stress conditions, including thermal stress (20, 37, and 42 °C), non-fermentable carbon sources (xylulose, mannitol, glycerol, sorbitol, ethanol, and sucrose), metal stresses (CaCl₂, MnCl₂, CsCl, AgNO₃, CuSO₄, and NiSO₄), oxidative stress (H₂O₂, PQ, and menadione), cell wall–perturbing agents (caspofungin, calcofluor white, SDS, caffeine, hygromycin B, and Congo red), cell membrane–perturbing agents (EDTA and NaCl), fluorescent dyes (rhodamine 6G, rhodamine B, and R123), polyenes (nystatin), azoles (fluconazole (FLC), itraconazole (ITR), miconazole (MCZ), and ketoconazole (KTC)), and other compounds (BER and curcumin), was performed. Most of the above-mentioned stresses, in comparison with WT cells, had no significant impact on growth of NKKY101 (Fig. S2), except in cases of PQ, BER, and R123, where increased susceptibility of NKKY101 strain was observed (Fig. 1D) accompanied with collateral high resistance to azoles (Fig. 1D; discussed below).

A single allele revertant strain was constructed by adding the *CDR6/ROA1* allele at its native locus in a NKKY101 strain designated NKKY102. The revertant strain was confirmed by semi-quantitative RT-PCR along with the WT and NKKY101 strains (Fig. S3). This revertant strain NKKY102 was used to test whether the observed changes in drug susceptibility could be rescued. For this, a serial dilution spot assay as well as a planktonic growth assay of WT, NKKY101, and NKKY102 strains on BER, R123, and PQ was performed. As depicted in Fig. 2A, the addition of a *CDR6/ROA1* single allele in the NKKY101 strain was able to revert back the phenotype of NKKY101. The impact of Cdr6/Roa1 level on drug susceptibility was further assessed in a strain overexpressing untagged Cdr6/Roa1. This strain was constructed in *C. albicans* by integrating *CDR6/ROA1* under the control of pTDH3 promoter at *RPS1* locus in the SC5314 and designated NKKY103 (Fig. S3). Of note, as expected, the *CDR6/ROA1*-overexpressing strain NKKY103 showed higher resistance toward BER and PQ as compared with WT, NKKY101, and NKKY102 (Fig. 2A).

Fluorescent BER and R123 are substrates of Cdr6/Roa1

Cdr6/Roa1 is a PM-localized PDR subfamily transporter; therefore, it was reasonable to speculate that it could also act as an exporter. Because the overexpression of Cdr6 leads to higher resistance to BER (Fig. 2A), we checked whether these fluorescent molecules (BER and R123) could act as substrates of Cdr6. FACS-based accumulation assays of R123 and BER for WT, NKKY101, NKKY102, and NKKY103 strains revealed that the *CDR6/ROA1* null mutant NKKY101 accumulated higher amounts of R123 and BER as compared with other strains. As expected, the *CDR6/ROA1*-overexpressing NKKY103 strain showed the lowest amount of accumulation as compared with other strains (Fig. 2, B and C).

***CDR6/NKKY101* null mutant shows reduced intracellular accumulation of azoles**

As mentioned, our screen (Fig. 1D) revealed that whereas the *CDR6/ROA1* null mutant NKKY101 displayed higher susceptibility to several xenobiotics, it was particularly resistant to azoles, such as triazoles (FLC and ITR) and imidazoles (MCZ and KTC) (Fig. 1D). This phenotype was quite surprising; therefore, further validation was done by employing multiple assays using different growth conditions (solid medium and liquid medium). As depicted in Fig. 3A, the spot assays revealed that the NKKY101 strain is indeed azole-resistant as compared with the WT, NKKY102, and NKKY103 strains. This was further confirmed by agar drug diffusion assays, where the size of the inhibitory zone (halo) indicates the extent of drug susceptibility. It was observed that the zone of inhibition was smallest in the NKKY101 strain as compared with the WT, NKKY102, and NKKY103 strains, pointing to the fact that the mutant strain is highly resistant to the tested drug (Fig. 3B). The liquid growth test further confirmed the resistant phenotype of the NKKY101 strain. It was evident from the growth analysis until 24 h that in the presence of FLC, the NKKY101 mutant strain showed significantly enhanced growth as compared with WT, NKKY102, and NKKY103 strains (Fig. 3C). During the course of our study, Jiang *et al.* (25) also reported azole resistance with deletion of *orf19.4531*; however, the study did not provide any explanation for the mechanism of resistance (25).

The fact that resistance to azoles in the *CDR6/ROA1* null mutant NKKY101 is observed in the absence of the transporter suggests that the transporter does not play a role as an azole exporter. We examined whether the import of FLC is affected in the NKKY101 strain, which may contribute to the observed resistance. For measuring drug accumulation in the *CDR6/ROA1* null mutant NKKY101, radiolabeled [³H]FLC was used as described previously (33). The intracellular accumulation of radiolabeled [³H]FLC was quantitated in the WT, NKKY101, NKKY102, and NKKY103 strains in the absence and presence of glucose. As depicted in Fig. 3 (D and E), a significantly lower level of FLC accumulated in the *CDR6/ROA1* null mutant NKKY101 as compared with the WT and NKKY103 strains. The *CDR6/ROA1*-overexpressing strain NKKY103 showed the highest accumulation of FLC and highest susceptibility to azoles (Fig. 3, D and E). The difference in FLC accumulation was intensified between the WT and *CDR6/ROA1* null mutant




Figure 2. R123, BER, and PQ are substrates of the *Cdr6/Roa1* transporter. *A*, left, comparison of growth by spot dilution assays for *C. albicans* WT, *CDR6/ROA1* null mutant NKKY101, *CDR6/ROA1* revertant NKKY102, and *CDR6/ROA1* overexpression strain NKKY103 cells onto R123, BER, and PQ at the indicated concentrations in YEPD agar plates. Right, MIC_{50} values for these strains, obtained by use of a broth microdilution assay, starting with the indicated concentration of xenobiotics in the first well in YEPD medium, as described under “Experimental procedures.” For each strain, optical densities were averaged for duplicate measurements, and relative growths (as compared with drug-free growth) were displayed with color as indicated with the color bar using three-color heat maps. *B*, R123 accumulation assay in WT, NKKY101, NKKY102, and NKKY103 strains cells using FACS. *n* = 10,000 cells for each sample. *C*, BER accumulation assay in WT, NKKY101, NKKY102, and NKKY103 strains cells using FACS. *n* = 10,000 cells for each sample.

NKKY101 when the assay was performed in the absence of the carbon source glucose (Fig. 3D). The absence of glucose inhibits ATP-dependent FLC efflux transporters, which may otherwise mask the drug accumulation measurements during the assay.

Deletion of *CDR6/ROA1* leads to higher PM rigidity

Because changes in the physical state of the PM have earlier been shown to impact drug diffusion and susceptibility of

C. albicans cells (8–10, 16), we explored whether the intracellular drug accumulation observed could be correlated to any change in PM fluidity. To examine this possibility, we used fluorescence recovery after photobleaching (FRAP)-based lateral mobility analysis by employing the FAST-DII dye, which we have used earlier for measuring the PM fluidity in yeast cells (16). As described under “Experimental procedures,” WT, NKKY101, and NKKY102 cells were incubated with the lipid




Figure 3. CDR6/ROA1 deletion leads to resistance toward azoles and low accumulation of azoles. *A*, comparison of growth by spot dilution assays between WT, NKKY101, NKKY102, and NKKY103 strains. A 5-fold serial dilution of each strain was spotted on YEPD agar plates containing the triazoles (FLC and ITR) and imidazoles (KTC and MCZ) at the indicated concentrations and grown for 48 h at 30 °C. *B*, drug resistance profiles of WT, NKKY101, NKKY102, and NKKY103 strains on FLC by a filter disk assay as described under “Experimental procedures.” *C*, growth curve of WT, NKKY101, NKKY102, and NKKY103 strains in YEPD medium in the absence (*left*) and presence (*right*) of FLC. *D*, [³H]FLC accumulation levels in *C. albicans* WT, NKKY101, NKKY102, and NKKY103 strains were measured at 24 h in the absence of glucose after cells were carbon-starved for 3 h. *E*, [³H]FLC accumulation levels in *C. albicans* WT, NKKY101, NKKY102, and NKKY103 strains were measured at 24 h in the presence of 2% glucose after cells were carbon-starved for 3 h. All experiments were performed in biological triplicate, and the results are shown as means \pm S.D. (error bars). A statistical significance value (**, $p \leq 0.01$; *, $p \leq 0.05$; ns, not significantly different) was employed using unpaired Student’s *t* test.

probe FAST-Dil dye. A particular region of FAST-Dil dye-stained PM was selected and photobleached. The same region was imaged over time, and recovery of FAST-Dil dye fluorescence was measured. Recovery is due to lateral movement of the FAST-Dil dye from the unbleached region of PM to the bleached region (Fig. 4A). The time to recover the fluorescence in the bleached area is dependent on the physical state of the PM. For instance, higher membrane fluidity would lead to faster fluorescence recovery (16). Fig. 4B depicts the representative fluorescence recovery experiment images of WT, NKKY101, and NKKY102 strains. As shown in the overlapping recovery plot, the WT shows the fastest recovery, followed by the NKKY102 and NKKY101 strains, respectively (Fig. 4C).


Next, using different recovery data sets, we calculated the diffusion coefficient (as described under “Experimental procedures”). As evident from Fig. 4D, NKKY101 mutant showed the lowest diffusion coefficient value ($0.26 \pm 0.01 \times 10^{-9} \text{ cm}^2/\text{s}$), whereas the WT strain showed the maximum diffusion coefficient value ($0.89 \pm 0.10 \times 10^{-9} \text{ cm}^2/\text{s}$). Interestingly, the single allele revertant strain NKKY102 showed an intermediate diffusion coefficient value ($0.47 \pm 0.06 \times 10^{-9} \text{ cm}^2/\text{s}$). Further, we calculated the mobile fraction as described under “Experimental procedures.” Notably, the mobile fraction of the dye was similar for the WT (47.6 ± 2.1), NKKY101 (47.7 ± 3.3), and NKKY102 (49.5 ± 2.2) strains. This indicated that fluorescence recovery is comparable in WT, NKKY101, and NKKY102

Cdr6/Roa1, a plasma membrane ABC transporter of *C. albicans*

strains; however, the rate of recovery is significantly different. We conclude from our FRAP experiments that the Cdr6/Roa1 protein is required to maintain the PM fluidity, and its absence makes the PM more rigid, resulting in reduced movement of azole drugs across the PM.

CDR6/ROA1 null mutant shows high PM dipole potential

Membrane dipole potential is the electrostatic potential difference within the membrane due to the nonrandom arrangement of amphiphile dipoles and solvent (water) molecules at the interface. As the origin of dipole potential is due to the



“nonrandom” (restricted) orientation of lipid and solvent dipoles, a decrease in membrane fluidity could result in an increase in population of nonrandom dipoles, leading to an increase in membrane dipole potential. To explore the effect of *CDR6/ROA1* deletion on the PM dipole potential of *C. albicans*, we stained the PM fractions of WT, NKKY101, and NKKY102 strains using the voltage-sensitive probe pyridinium, 4-(2-(6-dioctylamino)-2-naphthalenyl)ethenyl)-1-(3-sulfopropyl)-inner salt (di-8-ANEPPS) and measured the PM dipole potential as described under “Experimental procedures.” We observed that the NKKY101 strain had significantly higher PM dipole potential as compared with the WT and NKKY102 strains (Fig. 4E).

Disruption of *CDR6/ROA1* perturbs lipid homeostasis

Lipids are an essential component of the PM, and any changes in lipid homeostasis can alter the PM fluidity status. It has been reported earlier that the level of several ABC transporters in yeast and other organisms also impacts lipid homeostasis (30, 34, 35). The major fungal plasma membrane sterol, ergosterol, is an important lipid species that usually provides rigidity to the PM (9, 36). It is observed that the susceptibility to azole drugs that target the ergosterol biosynthesis pathway is affected by PM ergosterol levels (16, 28, 37).

Our observed changes in intracellular drug accumulation and increased resistance to azoles in NKKY101 cells could be the result of imbalances in lipid homeostasis. This possibility was explored by performing high-throughput MS-based lipidome analysis using ESI-MS/MS. Our lipidome analysis revealed no major change in ergosterol and other sterol species content in NKKY101 strain as compared with WT (Fig. 5A). The zymosterol level was found to be significantly low in the case of the NKKY101 strain (Fig. 5A). However, a decrease in the level of zymosterol does not contribute to azole resistance. Together, the sterol analysis overruled the possibility of a role of sterols in influencing membrane fluidity and the phenotype of NKKY101 strain.

The major phosphoglycerides (PGLs), which include lysophosphatidylcholine, phosphatidylcholine, lysophosphatidylethanolamine, phosphatidylethanolamine (PE), phosphatidylserine, phosphatidylinositol, phosphatidic acid, and phosphatidylglycerol, were detected in our analysis. No major variation between WT and NKKY101 strain was observed. However, as depicted in Fig. 5B, PE content was significantly high, whereas phosphatidylinositol was significantly low in the NKKY101 strain as compared with the WT strain. Even small

changes in the levels of these PGLs can play an important role in the PM fluidity, particularly PE which has been assigned as a key regulator of the PM fluidity (38).

Inactivation of *CDR6/ROA1* results in up-regulation of ribosome biogenesis genes

We performed a microarray-based genome-wide transcriptome analysis of WT and NKKY101 strains to assess the molecular basis of observed azole resistance. The comparative transcriptome analysis revealed that none of the known mechanisms of azole resistance involving expression of major drug exporters and ERG genes were significantly changed between the NKKY101 and WT strains. However, the comparative transcriptomic profile showed significant (≥ 2 -fold) down-regulation and up-regulation of 135 and 116 genes, respectively, in the NKKY101 strain as compared with WT (Table S2). The transcription profile was further analyzed using CGD Go-slim mapper and was annotated on the basis of biological processes. Specifically, in the NKKY101 strain, expression of genes encoding proteins involved in ribosome biogenesis, RNA metabolic process, organelle organization, and filamentous growth was increased, whereas expression of carbohydrate metabolic process, cellular protein modification process, and cellular homeostasis was generally decreased (Fig. 6A). The genes belonging to the transport, response to chemicals, regulation of biological process, response to stress, and pathogenesis categories were differentially regulated (up- and down-regulated) in the NKKY101 strain as compared with WT (Fig. 6A).

For a better understanding of the roles of genes belonging to more than one biological process, five major categories from up- and down-regulated genes were selected to make an interaction map (based on the biological processes in which they are involved) using Cytoscape software. As depicted in Fig. 6B, except for the carbohydrate metabolic process, other categories shared many common genes. Interestingly, the major portion ($\sim 31\%$ of up-regulated genes; 35 genes) among up-regulated genes belongs to ribosome biogenesis, which shared most of the genes with the RNA metabolic process category (Fig. 6, A and B).

Hyperactivation of *Tor1* leads to up-regulation of ribosome biogenesis in NKKY101 strain

Our microarray data revealed that 35 genes related to ribosome biogenesis were among the most up-regulated gene category in the NKKY101 strain (Fig. 6). It is an established fact that *Tor1* (target of rapamycin 1) regulates ribosome biogenesis in a

Figure 4. Disruption of *CDR6/ROA1* causes high PM rigidity. A, schematic of the FRAP. PM-bound *FAST-Dil* was photobleached. The same region was imaged over time, and recovery of *FAST-Dil* dye fluorescence was measured. Recovery was due to lateral diffusion of *FAST-Dil* dye from the unbleached region of PM to the bleached region. The time to recover the fluorescence in the bleach area is dependent on the physical state of the PM; higher membrane fluidity would lead to faster fluorescence recovery. B, images of *FAST-Dil* dye-labeled PM of WT, NKKY101, and NKKY103 cells (left column, $t = 0$ s, prebleach). A region of interest (ROI; yellow circle) was photobleached, and cells were imaged immediately thereafter (second column images, bleach) and after 120 s postbleach (third column, recovery). C, a qualitative estimate of rate of recovery can be obtained by comparing the slopes of the overlapped recovery curve, demonstrating slowest recovery in *CDR6/ROA1* null mutant NKKY101 in comparison with WT and *CDR6/ROA1* revertant NKKY102 strains. D, diffusion coefficients calculated for WT, NKKY101, and NKKY103 strains from quantitative FRAP experiments as described under “Experimental procedures” and plotted as a histogram. The experiment was performed in biological triplicates, and values are the means \pm S.E. (error bars). A statistical significance value (***, $p \leq 0.001$; **, $p \leq 0.01$) was employed using Student’s *t* test. E, PM dipole potential measured using di-8-ANEPPS. Change in dipole potential was measured utilizing di-8-ANEPPS after incorporation into the PM of WT, NKKY101, and NKKY103 strains. Dipole potential values were calculated from the fluorescence ratio (*R*), defined as the ratio of fluorescence intensity at an excitation wavelength of 420 nm to that at 520 nm (emission at 670 nm in both cases; see “Experimental procedures”). Experiments were performed at least in triplicate, and results are shown as means \pm S.D. (error bars). ***, $p \leq 0.001$; ns, not significantly different, calculated using an unpaired Student’s *t* test.

Cdr6/Roa1, a plasma membrane ABC transporter of *C. albicans*




Figure 5. Lipid profile of *CDR6/ROA1* null NKKY101 mutant as compared with WT. *A*, sterol species level in WT and NKKY101 strain; data represent the percentage of total sterol mass spectral signal after normalization to internal standards. *B*, levels of PGL classes in WT and NKKY101 strain; the data represent the percentage of total PGL mass spectral signal after normalization to internal standards. Experiments were performed in biological quadruplet, and results are shown as means \pm S.E. (error bars). A statistical significance value of $p \leq 0.05$ (*) was calculated using Student's *t* test. The raw data for the graphs are available as Table S1. LPC, lysophosphatidylcholine; PC, phosphatidylcholine; LPE, lysophosphatidylethanolamine; PS, phosphatidylserine; PI, phosphatidylinositol; PA, phosphatidic acid; PG, phosphatidylglycerol.

positive manner, and Tor1 function is inhibited by rapamycin (39, 40). We compared the growth of WT, NKKY101, and NKKY102 strains in the presence of rapamycin using a spot assay. Fig. 7A shows that the NKKY101 strain showed a resistant phenotype on rapamycin as compared with WT, and this phenotype could be rescued in the revertant strain NKKY102. The resistance to rapamycin pointed to hyperactivation of Tor1 in the NKKY101 strain. To validate further that the observed up-regulation of the ribosome biogenesis gene in the NKKY101 strain is because of hyperactive Tor1, we treated the NKKY101 cells with 4 and 8 ng/ml concentrations of rapamycin (an inhibitor of Tor1) and checked the expression of some of the randomly selected ribosome biogenesis genes by quantitative RT-PCR. As depicted in Fig. S4A, the expression of selected genes was lower in rapamycin-treated cells in a dose-dependent manner in comparison with untreated cells. This suggests that the up-regulation of ribosome biogenesis genes in NKKY101 strain is linked to the hyperactivation of Tor1.

Considering that Kns1 kinase in *S. cerevisiae* negatively regulates the ribosome biogenesis and Tor1 relieves the impact of Kns1 from ribosome biogenesis by negatively regulating *KNS1* transcript expression (19), our observed \sim 3-fold down-regulation of orf19.4979, a homologue of *S. cerevisiae* Kns1 kinase in NKKY101, strongly indicates that the impact of hyperactive Tor1 on Kns1 kinase expression is conserved in *C. albicans* (Fig. 7B). The negative impact of Tor1 on *KNS1* transcript in the NKKY101 strain was further validated by the quantification of the expression of the *KNS1* transcript in rapamycin-treated conditions, where inhibition of Tor1 by rapamycin induced the expression of *KNS1* (Fig. S4B).

Next, we performed spot assays of the WT, NKKY101, and NKKY102 strains in the presence of protein synthesis inhibitors anisomycin (ANM) and cycloheximide (CHX) (41, 42). Our spot assay showed that growth of the NKKY101 strain was much better as compared with WT and NKKY102 strains in the presence of protein synthesis inhibitors (Fig. 7C). Of note, the




Figure 6. The comparative transcriptomic profile of *CDR6/ROA1* null mutant NKKY101. *A*, the genes with ≥ 2 -fold change are annotated on the basis of biological processes using CGD Go-slim mapper. The x axis indicates the biological functional categories, and the y axis indicates the number of genes. *Left column*, categories of genes that are only up-regulated; *middle column*, categories of genes that are up- and down-regulated; *right column*, the categories of genes that are only down-regulated. *B*, interaction map of the *CDR6/ROA1* null mutant NKKY101 using five major categories from up- and down-regulated genes. Clustering was based on gene involvement in biological functions using Cytoscape software. *Red and green circles*, genes down- and up-regulating, respectively. The size of the circle is proportional to -fold change (the higher the -fold change, the bigger the size of the circle).

Cdr6/Roa1, a plasma membrane ABC transporter of *C. albicans*




Figure 7. Hyperactivation of Tor1 leads to up-regulation of ribosome biogenesis in the absence of *CDR6/ROA1*. A, analysis of Tor1 activation by comparison of growth in the presence of rapamycin at the indicated concentrations by spot dilution assays for WT, *CDR6/ROA1* null strain NKKY101, and *CDR6/ROA1* revertant strain NKKY102. A 5-fold serial dilution of each strain was spotted onto rapamycin at the indicated concentrations on YEPE agar plates and grown for 48–60 h at 30 °C. The resistant phenotype of the NKKY101 strain suggests hyperactivation of Tor1 in comparison with WT and NKKY102 strains. B, validation of microarray data of *KNS1* expression by qRT-PCR in NKKY101 mutant compared with WT. Data (mean ± S.E. (error bars) of biological replicate with technical quadruplets) were normalized to an internal *ACT1* mRNA control and represented as percentage relative expression in the mutant cultures compared with the wild-type cells. Statistical analysis was performed using Student's *t* test (**, $p \leq 0.01$). C, a comparison of growth in the presence of protein synthesis inhibitors by spot dilution assays between WT, NKKY101, and NKKY102 strains. A 5-fold serial dilution of each strain was spotted onto ANM and CHX at the indicated concentrations on YEPE agar plates and grown for 48 h at 30 °C. D, left, MIPC level in WT and NKKY101 strains; data represent the percentage of total MIPC mass spectral signal after normalization to internal standards. Right, IPC level in WT and NKKY101 strains; data represent the percentage of total IPC mass spectral signal after normalization to internal standards. E, WT, *CDR6/ROA1* null strain NKKY101, and *CDR6/ROA1* revertant strain NKKY102 were analyzed for growth on YEPE agar plates in the presence of myriocin at the indicated concentrations and incubated at 30 °C for 48 h. F, model for *CDR6/ROA1* deletion effects on ribosome biogenesis and complex sphingolipid biosynthesis via TOR signaling. In the absence of *Cdr6/Roa1* protein, the Tor1 becomes active, which down-regulates the *KNS1* transcript and also induces ribosome biogenesis, thereby enabling cells to survive in the presence of protein synthesis inhibitors. Tor1 suppresses complex sphingolipid biosynthesis by inhibition of the SPT enzymatic step.

induction of ribosome biogenesis encourages protein synthesis, thus overcoming the growth inhibition by protein synthesis inhibitors (43, 44). Finally, we concluded from this experiment that deletion of *CDR6/ROA1* hyperactivates Tor1, which ultimately drives ribosome biogenesis (Fig. 7F).

Tor1 hyperactivation in NKKY101 mutant inhibits the complex sphingolipid biosynthesis

Recent studies have suggested that Tor1 negatively regulates the complex sphingolipids synthesis by inhibiting the Orm phosphorylation (45, 46). In *S. cerevisiae*, it has been shown that

Orm proteins negatively regulate the synthesis of sphingolipids by inhibiting the serine palmitoyltransferase (SPT) enzyme, and phosphorylation of Orm proteins relieves their inhibitory activity (45, 47, 48). Because we observed hyperactivation of Tor1 in the NKKY101 strain, the complex sphingolipid level in our lipidome data for NKKY101 and WT strains was analyzed. As expected, the inhibitory effect of hyperactive Tor1 on sphingolipid synthesis was evident, which was reflected in the lower amount of complex sphingolipids (IPC and MIPC) in NKKY101 as compared with WT strain (Fig. 7D).

To validate whether in *C. albicans* the observed Tor1 inhibitory effect on sphingolipids synthesis is because of SPT inhibition, we performed spot assays of WT, NKKY101, and NKKY102 strains on myriocin (a specific inhibitor of SPT) (49). Growth in the presence of myriocin is strongly dependent on the SPT level, and inhibition of SPT makes cells susceptible to myriocin. As illustrated in Fig. 7E, the NKKY101 strain showed growth impairment in the presence of myriocin as compared with WT and NKKY102 strain. This validates that in the NKKY101 strain of *C. albicans*, Tor1 hyperactivation represses the SPT activity, resulting in decreased sphingolipid synthesis (Fig. 7F).

Hsp90 activation occurs via Tor1 in NKKY101 strain

Hsp90 is a molecular chaperone that plays a crucial role in antifungal drug resistance (50). Impairment of Hsp90 function converts azoles from fungistatic to fungicidal (50, 51). Hsp90 stabilizes the calcineurin protein, and its activation is essential for cells to survive in the presence of azoles (52–54). CK2 kinase phosphorylates Hsp90 and represses its activity in *C. albicans* and *S. cerevisiae* (20, 21). *S. cerevisiae* Kns1 kinase activates the CK2 kinase by phosphorylation of Ckb1 (a regulatory subunit of CK2 kinase), and Tor1 negatively regulates the expression of Kns1 kinase (18, 19). Thus, active Tor1 decreases CK2 kinase activity, which in turn activates Hsp90.

The observed down-regulation of Kns1 in the NKKY101 strain (Fig. 7B) prompted us to analyze whether it has any impact on CK2 kinase activity. For monitoring the CK2 kinase activity, the phosphorylation of Sic1, which is phosphorylated by the CK2 kinase at serine 201, was quantitated (55). Notably, *CDR6/ROA1* null mutant NKKY101 showed significantly lowered phosphorylation of Sic1 at 4 and 6 min (Fig. 8A). This implied that, similar to *S. cerevisiae* (18), the low level of Kns1 kinase activity also has a negative impact on CK2 kinase activity in *C. albicans*.

We observed decreased CK2 kinase activity in the NKKY101 strain, implying that Hsp90 function may be induced in this strain. To determine whether decreased CK2 kinase activity in the NKKY101 strain activates Hsp90, we evaluated the activity of mitogen-activated protein kinase Hog1 (21, 56) and heat shock transcription factor Hsf1, which are downstream effectors of Hsp90 (57, 58).

Hog1 requires active Hsp90 to warrant its activation by phosphorylation (21, 56). As expected, we observed a high amount of phosphorylated Hog1 in the NKKY101 strain as compared with WT and NKKY102 strains (Fig. 8B). The results were confirmed by experiments in biological triplicate (Fig. S5). The Tor1-dependent high amount of Hog1 phosphorylation in

NKKY101 strain was further validated by measuring the Hog1 phosphorylation in NKKY101 strain after treatment with rapamycin as described under “Experimental procedures.” As expected, the inhibition of Tor1 by rapamycin resulted in a decrease in Hog1 phosphorylation in the treated sample in comparison with the untreated sample (Fig. 8C).

We further validated the Hsp90 activation in NKKY101 strain by monitoring the repression of the *HSP70* gene, for which basal level expression requires active Hsf1 TF (59). Hsp90 exerts a suppressive effect on Hsf1; thus, activation of Hsp90 represses Hsf1-dependent genes. As expected, in our microarray data, we also observed ~2.4-fold down-regulation of *HSP70* in NKKY101 strain as compared with WT (Fig. 8D). These results indicate that Hsp90 is present in a hyperactive state in *CDR6/ROA1* null mutant NKKY10.

It is a well-established fact that Hsp90 stabilizes the catalytic subunit of the calcineurin protein by interacting with it, and calcineurin provides resistance against azoles by activating the calcineurin-dependent pathway (52, 60). Inhibition of Hsp90 activity using Hsp90-specific inhibitors also shows a negative impact on calcineurin function (22). Our results suggest that in the NKKY101 strain, hyperactive Tor1 influences the Hsp90 activity in a positive manner by modulating the CK2 kinase activity via effector kinase Kns1 and active Hsp90, leading to an activation of the calcineurin protein, thus contributing to azole resistance in the NKKY101 strain (Fig. 8E).

***Cdr6/Roa1* is not required for virulence**

In our recent studies, we reported that various transporter proteins of *C. albicans* perform diverse functions and are also required to maintain the virulence (30, 61). Whether *Cdr6/Roa1* played any role in virulence was examined in a mouse model. To test the infection capacity, mouse survival and kidney fungal burden assays were performed in immunocompetent BALB/c mice by injecting them with WT, NKKY101, and NKKY102 strains. It was observed that all of the *C. albicans* strains have similar virulence, and in all of the cases, no mice survived beyond 6 days (Fig. 9A). There was also no significant difference in overall kidney fungal burdens in mice infected with WT, NKKY101, and NKKY102 strains (Fig. 9B). These experiments ruled out any role of *Cdr6/Roa1* in virulence of *C. albicans*.

Absence of *Cdr6/Roa1* hampers *in vivo* azole efficacy

To evaluate the *in vivo* significance of the observed *in vitro* azole resistance in *CDR6/ROA1* null mutant NKKY101, we employed a mouse model of candidiasis. Immunocompetent female BALB/c mice were infected with the WT, NKKY101, and NKKY102 mutant cells via tail vein injection described under “Experimental procedures.” After 3 h of infection, FLC treatment was given intraperitoneally. The FLC treatment was followed for the next 2 days. The experimental regimen is depicted in Fig. 9C. Each day, three mice from each group were euthanized and enumerated for *C. albicans* burden in kidneys. Notably, as mentioned above, our *in vivo* data revealed that *CDR6/ROA1* null mutant NKKY101 did not affect virulence in the mouse model (Fig. 9, A and B); however, when infection was challenged with FLC, interesting correlations were observed.

Cdr6/Roa1, a plasma membrane ABC transporter of *C. albicans*




Figure 8. Tor1 activation in NKKY101 strain causes Hsp90 activation via CK2 kinase. *A*, *CDR6/ROA1* deletion suppresses CK2 activity. CK2 activity was monitored in an *in vitro* assay using protein lysates from *C. albicans* WT and NKKY101 strains, using recombinant Sic1 as a substrate. The assay was performed in biological duplicates with technical replicates. *Error bars*, S.D.; *, $p < 0.05$ (Student's *t* test). *B*, the *CDR6/ROA1* deletion causes Hog1 activation. NaCl was used as a positive control to detect the active phosphorylated form of Hog1. The phosphorylated Hog1 level is low in the WT and *CDR6/ROA1* revertant NKKY102 strains under basal conditions and induced in the presence of NaCl. However, the phosphorylated Hog1 level is high in the *CDR6/ROA1* null strain NKKY101 even in basal conditions. The addition of NaCl increased the phosphorylated Hog1 in the null strain. Bands were quantified using Bio-Rad Image Lab software, and the ratio of phosphorylated Hog1 to total Hog1 was plotted for WT, NKKY101, and NKKY102 strains for basal conditions (without NaCl induction). A similar trend of phosphorylated Hog1 was observed in biological triplicate experiments for basal conditions (Fig. S5). *C*, Hog1 activation in *CDR6/ROA1* null strain NKKY101 is Tor1-dependent. Rapamycin was used as a Tor1 inhibitor. The phosphorylated Hog1 level decreased in *CDR6/ROA1* null strain NKKY101 when treated with rapamycin (4 and 8 ng/ml) in comparison with untreated conditions. *D*, validation of microarray data of *HSP70* expression by qRT-PCR in NKKY101 mutant compared with WT. Data (mean \pm S.E. (*error bars*) of biological replicate with technical triplicates) were normalized to an internal *ACT1* mRNA control and represent percentage relative expression in the mutant cultures compared with the wild-type cells. Statistical analysis was performed using Student's *t* test (**, $p \leq 0.01$). *E*, model for Hsp90 activation. Deletion of *CDR6/ROA1* activates the Tor1, which down-regulates the *KNS1* transcript, resulting in decreased CK2 kinase activity. This decrease in CK2 kinase activity causes activation of Hsp90 and its client proteins.

Higher kidney fungal burden was observed from kidneys of mice infected with *CDR6/ROA1* null mutant NKKY101 as compared with WT and *CDR6/ROA1* revertant NKKY102 strains (Fig. 9C). Of note, the fungal burden was significantly higher after 24 and 72 h in mice infected with *CDR6/ROA1* null mutant NKKY101 in comparison with WT ($p < 0.001$ for 24 and 72 h) and *CDR6/ROA1* revertant NKKY102 strain ($p < 0.001$ for 24 and 72 h). Together, the increased fungal burdens from kidneys of mice infected with *CDR6/ROA1* null mutant point to the role of Cdr6/Roa1 in azole resistance *in vivo* during FLC treatment.

Discussion

Cdr1 (*Candida* drug resistance 1) belongs to the largest ABCG/PDR subfamily of transporters in *C. albicans* and is well characterized as a multidrug exporter imparting MDR. A close homologue of Cdr1, designated Cdr2, has also been shown to

impact clinical drug resistance (7). However, the role of other members of this subfamily remains poorly described. For instance, none of the members are proven transporters. A few of the ABCG/PDR members have been shown to translocate phosphoglycerides between the two monolayers of the lipid bilayer and maintain membrane lipid asymmetry (27). The present study deals with a poorly characterized PDR subfamily member, orf19.4531, which encodes a PM-localized protein. In a recent report (25), this particular protein has been shown to be localized on a punctuated compartment adjacent to the vacuolar membrane. However, the authors could not detect any protein expression in their Western blot. We speculate that proper expression of the protein could not be achieved with the system used in that study. Our present data from confocal microscopy and Western blotting confirm that localization of Cdr6/Roa1 is in the PM. Our functional analysis revealed that, similar to PM-localized CDR proteins, orf19.4531 also




Figure 9. Absence of *CDR6/ROA1* hampers *in vivo* azole therapy. *A*, the survival curve of mice infected with *C. albicans* WT, NKKY101, and NKKY102 shows similar patterns; all of the mice succumbed to infection within 6 days postinfection. *B*, fungal kidney burden that was examined from moribund mice was not statistically different between WT-, NKKY101-, and NKKY102-infected mice. *C*, on average, cfu recovered from kidneys after a short FLC therapy (20 mg/kg intraperitoneally once after 3 h postinfection, once on day 1 and once on day 2 postinfection) are significantly higher in NKKY101-infected mice compared with WT and NKKY102 strains, as determined at the indicated times (24, 48, and 72 h). Statistically significant differences in the cfu levels between WT, NKKY101, and NKKY102 strains are indicated. **, $p \leq 0.01$ (Student's *t* test).

functions as a multidrug exporter and particularly effluxes BER, R123, and PQ. We therefore designated orf19.4531 as *CDR6/ROA1*.

It was observed here that homozygous deletion of *CDR6/ROA1* leads to an increased resistance to azoles. This observation is consistent with a previous report (25). The [³H]FLC accumulation data confirmed here a low intracellular accumulation of the drug in *CDR6/ROA1* null mutant NKKY101. Additionally, high-throughput lipidomics and FRAP data suggested that the *CDR6/ROA1* deletion resulted in lipid imbalances and increased rigidity of the PM, thereby providing a plausible explanation for the observed reduced entry of azole into the *CDR6/ROA1* null mutant. High-throughput lipid analysis further revealed no significant imbalance in ergosterol levels. However, PE content was significantly higher in the *CDR6/ROA1* null mutant. According to recent reports, PE could also act as a key regulator of PM fluidity, wherein an increase in its level leads to high PM rigidity (38). Our lipidome data support the conclusions of Jiang *et al.* (25), who have recently suggested a probable role of orf19.4531 in the regulation of transport and redistribution of lipids across different membranes, resulting in an impact on the plasma membrane potential. The observed

high PM rigidity in *CDR6/ROA1* null could be a plausible reason for the increased membrane potential observed by Jiang *et al.* (25). Additionally, this high PM rigidity could result in an increase in the population of nonrandom dipoles, leading to an increase in membrane dipole potential. Our dipole potential measurements showed that the NKKY101 strain has significantly higher PM dipole potential as compared with WT and NKKY102 strains (Fig. 4E).

Together, an increase in PE content in the absence of *Cdr6/Roa1* in PM results in an increase in membrane rigidity, which impacts membrane potential and PM dipole potential, resulting in a decrease in drug entry into the cells and enhanced azole resistance. These observations are also consistent with the earlier reports that the physical state of the PM impacts intracellular drug accumulation and drug susceptibility of *C. albicans* cells (8–10, 16).

We explored the cause of observed enhanced resistance to azoles of the *CDR6/ROA1* null mutant by performing whole-genome transcriptomic analysis. These data confirmed the absence of ERG gene regulation and also of the azole drug transporters (*Cdr1*, *Cdr2*, and *Mdr1*) involved in clinical drug resistance. Notably, genes involved in ribosome biogenesis and

Cdr6/Roa1, a plasma membrane ABC transporter of *C. albicans*




Figure 10. Proposed model for *C. albicans* Cdr6/Roa1. Cdr6/Roa1 is a PM-localized transporter that effluxes BER (green circles), R123 (violet circles), and PQ (red circles). Deletion of *CDR6/ROA1* leads to increased PE levels and high plasma membrane rigidity, resulting in reduced entry of azoles (sky blue circles) inside the cells, and provides resistance against azoles. The absence of Cdr6/Roa1 activates Tor1, which affects multiple cellular functions, including (i) induction of ribosome biogenesis, which provides resistance to protein synthesis inhibitors (CHX and ANM); (ii) Hsp90 activation, which acts on the client protein calcineurin and provides resistance to azoles; and (iii) inhibition of the SPT enzymatic step, which results in suppression of complex sphingolipid biosynthesis.

RNA processing were up-regulated categories in the *CDR6/ROA1* null mutant NKKY101 as compared with WT (Fig. 6). It is worth mentioning that well-conserved rapamycin-sensitive Tor protein kinases regulate ribosome biogenesis and various other processes (62). In *S. cerevisiae*, two Tor proteins (Tor1 and Tor2) have been characterized, whereas in *C. albicans*, a single Tor homolog is present (63). *S. cerevisiae* Tor1 negatively regulates expression of Kns1 kinase and relieves its negative impact from the ribosome biogenesis (19). Our growth analysis in the presence of rapamycin demonstrates that TOR is hyperactivated in the *CDR6/ROA1* null mutant NKKY101 and induces ribosome biogenesis. This was well supported by the repressed expression of *orf19.4979* (a homologue of the *S. cerevisiae* Kns1 kinase) transcript (Fig. 7B). Finally, enhanced growth of *CDR6/ROA1* null mutant NKKY101 as compared with WT in the presence of protein synthesis inhibitors (CHX and ANM) confirmed the impact of induced ribosome biogenesis on translation. To the best of our knowledge, this is the first study to demonstrate a role of the TOR signaling cascade in azole resistance in a pathogenic yeast drug transporter null mutant (Fig. 10).

Tor1 negatively regulates complex sphingolipid synthesis, which was evident from the observed decrease in complex sphingolipid biosynthesis in the *CDR6/ROA1* null mutant. This was further supported by the growth analysis in the presence of myriocin (a specific inhibitor of the sphingolipid biosynthesis rate-limiting enzyme SPT), where the NKKY101 strain showed a growth defect in comparison with WT. These observations indicated that Tor1 activation in *C. albicans* may suppress the biosynthesis of complex sphingolipids by inhibiting the SPT enzyme. In the case of *S. cerevisiae*, it is well established that Tor1 negatively regulates the complex sphingolipid synthesis by inhibiting Orm phosphorylation, where the non-phosphor-

ylated form of Orm proteins negatively regulates the synthesis of sphingolipids by inhibiting the SPT enzyme (45, 46). The *S. cerevisiae* Tap42-Sit4-PP2A protein phosphatase complex activates the Npr1 kinase, which in turn phosphorylates Orm proteins. Tor1 imposes inhibition on the Tap42-Sit4-PP2A complex, thus inactivating Npr1 kinase (45, 46), preventing Orm phosphorylation, resulting in inhibition of SPT and repression of sphingolipids synthesis. Inhibition of Tor1 by rapamycin showed increased phosphorylated Orm proteins in *S. cerevisiae*, which can induce *de novo* synthesis of complex sphingolipids (46). Together, our study shows that Tor1 regulates complex sphingolipid biosynthesis, and the pathway appears to be evolutionarily conserved in *C. albicans*.

Hsp90 coordinates cellular circuitry essential for responses to drug-induced stress. Its post-translational modifications, such as phosphorylation, regulate its ability to interact and stabilize client proteins (17, 20, 64). Calcineurin, a protein phosphatase, is a client protein of Hsp90 that acts as a key mediator of Hsp90-dependent azole resistance in yeast (50, 52). Our results illustrate the role of Hsp90-dependent activation of calcineurin in azole resistance in the NKKY101. For instance, based on analysis of the Hsp90 client proteins, including the protein kinase Hog1 and heat shock transcription factor Hsf1, we observed that Hsp90 is present in the hyperactive state in the NKKY101. This particular state of Hsp90 is a consequence of hyperactive Tor1 in the NKKY101, which modulates the CK2 kinase activity via effector kinase Kns1. Thus, we demonstrate a dual mechanism in the NKKY101, where a high PM rigidity results in reduced intracellular accumulation of azoles and Tor1-dependent activation of Hsp90 and its client protein calcineurin, both leading to increase azole resistance. This was also well supported by an *in vivo* mouse model, where cells

infected with the NKKY101 strain displayed higher fungal burden in the presence of fluconazole (Fig. 9C).

Our results show increased activity of Tor1 in the *CDR6/ROA1* null mutant NKKY101. How TOR activity is regulated in *CDR6/ROA1* null mutant NKKY101 remains to be elucidated. We speculate that the alteration in PM tension in the *CDR6/ROA1* null mutant may be causing Tor1 activation, as it has been shown that the PM stress, due to membrane stretch or inhibition of sphingolipid synthesis, could activate the TOR signaling in *S. cerevisiae* (11). Mechanistic details and physiological relevance of Tor1 hyperactivity in *CDR6/ROA1* null mutant will be interesting to further investigate, as the absence of none of the other ABC transporters has shown such a phenotype. Further, a recent study by Bastidas *et al.* (65) has shown that inhibition of Tor1 by rapamycin leads to an induced expression (~34-fold) of *CDR6/ROA1* transcripts in *C. albicans*, implying that Tor1 and Cdr6/Roa1 may impose a reciprocal impact on each other.

In summary, we present the characterization of a PM-localized ABC drug transporter, Cdr6/Roa1, and provide evidence that *CDR6/ROA1* deletion leads to hyperactivation of Tor1, thus affecting multiple cellular functions, including Hsp90 activation, induction of ribosome biogenesis, and suppression of complex sphingolipid biosynthesis (Fig. 10). Our result highlights that Cdr6/Roa1 is an exporter of xenobiotics, and it also adopts multiple strategies to display collateral increased resistance to azoles.

Experimental procedures

Materials

The growth media YEPD (yeast extract/peptone/dextrose) and LB broth were purchased from Himedia (Mumbai, India). CuSO_4 , NiSO_4 , CaCl_2 , MnCl_2 , CsCl , AgNO_3 , NaCl , H_2O_2 , and SDS were obtained from Qualigens (Mumbai, India). The antifungal compounds PQ, caspofungin, calcofluor white, caffeine, hygromycin B, Congo red, rhodamine 6G, rhodamine B, R123, MG, nystatin, ITC, MCZ, KTC, FLC, BER, RAP, MYR, ANM, CHX, curcumin, and the chemicals sucrose, Tris buffer, DMSO, sorbitol, EDTA, poly-L-lysine, and TMA-DPH were purchased from Sigma. FLC was generously provided by Ranbaxy Laboratories (Gurgaon, Haryana, India). Di-8-ANEPPS and FAST-DiI were purchased from Molecular Probes/Invitrogen (Eugene, OR). Radioactive fluconazole ($[^3\text{H}]$ FLC; 481 GBq/mmol, 13 Ci/mmol, 1 $\mu\text{Ci}/\mu\text{l}$; 77 μM FLC) was custom-synthesized by Amersham Biosciences. The oligonucleotides used in the present study, as listed in Table S3, were obtained from Sigma Genosys (Bangalore, India).

Strains and culture conditions

The yeast strains used in the present study are listed in the Table S4. *C. albicans* strains were grown and maintained in YEPD medium. Strain stocks were made in 15% glycerol at -80°C and freshly revived in YEPD before use. Bacterial strain *Escherichia coli* DH5 α was used as a host for the construction and propagation of plasmids. *E. coli* cells were grown in LB medium containing 100 $\mu\text{g}/\text{ml}$ ampicillin (Amresco) or 25 $\mu\text{g}/\text{ml}$ chloramphenicol (Sigma-Aldrich) as required.

Plasmid constructions

To construct the *CDR6/ROA1*-specific knockout cassette, we ligated three fragments and cloned two fragments (500 bp upstream and 500 bp downstream of *CDR6/ROA1*) in pBlue-script KS⁺ vector in a single cloning step. For this purpose, we amplified 500 bp upstream and 500 bp downstream of the *CDR6/ROA1* ORF from *C. albicans* strain SC5314 by PCR using primer pairs *CDR6*-KpnI/*CDR6*-XhoI-NotI and *CDR6*-SacII-NotI/*CDR6*-SacI (Table S3). After digestion of PCR products (KpnI/NotI and NotI/SacI) and of the vector (KpnI/SacI), products were ligated to yield pNK1. Next the *SAT1* flipper cassette was isolated from pSF52A vector by XhoI and SacII digestion and cloned into pNK1 to give rise to pNK2.

For the *CDR6/ROA1* revertant, the 500-bp upstream region of *CDR6/ROA1* in pNK2 was replaced with the *CDR6/ROA1* ORF (open reading frame) along with its promoter. The *CDR6/ROA1* ORF was amplified along with its promoter from *C. albicans* SC5314 genomic DNA using *CDR6*-Rev-KpnI and *CDR6*-Rev-XhoI primers (Table S3). The PCR product was digested with KpnI and XhoI and cloned into pNK2 to yield pNK3.

To construct overexpression plasmids *Cip*-SAT-P_{TDH3}-*CDR6/ROA1* and *Cip*-SAT-P_{TDH3}-GFP-*CDR6/ROA1*-SP, we first amplified the orf19.4531 open reading frame using primers 4531FP and 4531R (Table S3) and transferred the resulting PCR product into the pDONR207 vector using InvitrogenTM GatewayTM BP ClonaseTM as described previously (66). orf19.4531 was subsequently transferred from the resulting donor plasmid pDONR207::orf19.4531 into the destination vectors *Cip*-SAT-P_{TDH3}-GTW and *Cip*-SAT-P_{TDH3}-GFP-GTW-SP using InvitrogenTM GatewayTM LR ClonaseTM (66). The *Cip*-SAT-P_{TDH3}-GTW vector is a derivative of plasmid *Cip*10 that carries the sequence for integration at the *RPS1* locus on *C. albicans* Chr1, the *SAT1* marker for nourseothricin resistance selection (32, 67), and a GatewayTM cassette flanked by the attR sequences and preceded by the P_{TDH3} constitutive promoter. The *Cip*-SAT-P_{TDH3}-GFP-GTW-SP vector is similar to *Cip*-SAT-P_{TDH3}-GTW except that it harbors the GFP open reading frame between P_{TDH3} and the GatewayTM cassette and a platform for molecular barcode cloning and IlluminaTM sequencing. The resulting plasmids, *Cip*-SAT-P_{TDH3}-*CDR6/ROA1* and *Cip*-SAT-P_{TDH3}-GFP-*CDR6/ROA1*, were then used to transform *C. albicans* SC5314 strain.

Yeast strain transformation

C. albicans strains were transformed by an electroporation method as reported previously (32), and selection was performed on YEPD plates containing nourseothricin.

C. albicans strain construction

CDR6 knockout strain construction—The *CDR6/ROA1* knockout cassette was removed from the pNK2 plasmid by KpnI/SacI digestion; integration was performed in *C. albicans* (SC5314) using an electroporation method (32). Southern blots were performed to confirm the first allele deletion, and the strain was designated NKKY100. To perform the second allele deletion, we removed the selection marker (*SAT1* cassette) from the transformants by growing them in yeast extract maltose medium as described previously (32). For deletion of the

Cdr6/Roa1, a plasma membrane ABC transporter of *C. albicans*

second allele, the integration was performed in the heterozygous null strain using the *CDR6/ROA1* knockout cassette and confirmed by Southern blotting and semiquantitative RT-PCR. The *CDR6/ROA1* homozygous null strain was designated as NKKY101.

***CDR6/ROA1* revertant strain construction**—The *CDR6/ROA1* revertant cassette was removed from the plasmid pNK3 by KpnI/SacI digestion, and transformation was performed in the nourseothricin-sensitive *CDR6/ROA1* homozygous null strain NKKY1011. The *CDR6/ROA1* revertant (NKKY102) strain construction was validated by semiquantitative RT-PCR.

***CDR6/ROA1* overexpression strain construction**—To construct the *CDR6/ROA1*-overexpressing strain in *C. albicans*, we linearized the CIP-SAT-P_{T_{TDH3}}-GFP-*CDR6/ROA1*-SP and CIP-SAT-P_{T_{TDH3}}-*CDR6/ROA1* plasmids with StuI and transformed *C. albicans* strain SC5314 to give rise to the GFP-tagged *CDR6/ROA1* overexpression strain (CA-*CDR6*) and untagged *CDR6/ROA1* overexpression strain (NKKY103), respectively.

Bioinformatic analysis

The phylogenetic tree was constructed using MEGA version 6 software (68). *Cdr6/Roa1* protein topology was predicted using the TOPOCONS software (69).

Isolation of plasma membrane and immunodetection of *Cdr6/Roa1*-GFP protein

PMs were prepared from WT and *Cdr6/Roa1*-GFP-expressing *C. albicans* strains using sucrose density gradient centrifugation (70). The PM fractions (80 µg) were separated by 8% PAGE, blotted, and probed with HRP-conjugated anti-GFP monoclonal antibody (Santa Cruz Biotechnology, Inc., Dallas, TX) as described previously (70). Pma1 was used as a PM fraction control as well as a loading control; it was detected using anti-Pma1p polyclonal antibody (a gift from Professor Ramon Serrano, Universidad Politecnica de Valencia-CSIC, Valencia, Spain). Pma1p antibodies were detected with HRP-conjugated goat anti-rabbit antibody.

Semiquantitative and quantitative RT-PCR

cDNA synthesis was performed using the RevertAid H Minus First Strand cDNA synthesis kit (Thermo Scientific) following the protocol described by the manufacturer. The semiquantitative RT-PCR was performed using cDNA product (1 µl) for the PCR amplification reaction (25 µl) using gene-specific primers (Table S3). Quantitative RT-PCR was performed using Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific) and Applied Biosystems® 7500 real-time PCR systems using gene-specific primers (Table S3). The *ACT1* gene signal was used for normalization, and results were compared between the *Ct* values of WT and NKKY101 mutant.

Drug susceptibility assays

Spot assay—The spot assay was performed using 5-fold serial dilutions with 5 µl of cells from each dilution spotted on YEPD plates with and without drug (30).

Planktonic growth assay—The planktonic growth assay was performed using a broth microdilution method in YEPD

medium with an inoculum of 1×10^4 cells/ml as described previously (71).

Agar drug diffusion assay—The assay was performed using an inoculum of 1×10^5 cells/ml as described previously (29).

BER and R123 accumulation assay

The accumulation of R123 and BER in *C. albicans* strains was measured by flow cytometry. Briefly, log phase cells were set to an A_{600} of 0.1 in PBS + 2% glucose. Then a 10 µM final concentration of R123 or BER was added to the culture, and the cells were incubated at 30 °C for 1 h. The cells were then washed twice with ice-cold PBS and analyzed with the FACSsort flow cytometer (BD Biosciences) using filter FL2 and filter FL1 for R123 and BER, respectively. A total of 10,000 events were considered. The analysis was performed using CellQuest software.

[³H]FLC accumulation assay

For the import assay with WT, NKKY101, and NKKY102 strains, 200 µl of concentrated, glucose-starved (3-h starvation) cell culture was added to 14-ml round bottom tubes containing 250 µl of YNB with or without glucose as well as 50 µl of 0.77 µM [³H]FLC (freshly diluted 1:100 from stock). The resulting final [³H]FLC concentration in each sample was 77 nM (23.6 ng/ml), which is significantly below the MIC₅₀ value for the strains. After a 24-h incubation with [³H]FLC, 200 µl of the treated cell solution was added to a fresh 14-ml round bottom tube containing 5 ml of stop solution (YNB + 20 mM (6 mg/liter) unlabeled FLC). The solution was then poured over prewetted glass fiber filters and dried. Another 5 ml of stop solution was poured over each filter to wash each sample again. The filters containing washed cells were transferred to 5-ml scintillation vials. 3 ml of scintillation mixture (Ecoscint XR, National Diagnostics, Atlanta, GA) was added, and the radioactivity associated with the filter was measured in a Beckman Coulter scintillation analyzer. Results were normalized to cpm per 1×10^8 cells. All experiments were performed as biological triplicates, and results are shown as means ± S.E. A statistical significance value of 0.05 was employed using an unpaired Student's *t* test.

Fluorescence imaging of labeled *C. albicans* and FRAP experiments

C. albicans staining with FAST-DiI was performed as described previously (16) with minor modifications. *C. albicans* culture was suspended at a density of 10^8 cells/ml in 1 M sorbitol, 0.1 M EDTA buffer and labeled using a final concentration of 10 µM FAST-DiI.

Confocal imaging was carried out on an inverted Zeiss LSM 510 Meta confocal microscope with a plan-apochromat ×100/1.4 numerical aperture oil-immersion objective using the 561-nm laser. Fluorescence emission was collected using the 575–630-nm bandpass filter with the confocal pinhole set at 1 Airy unit with a zoom factor of 7. The fluorescent periphery of the cell that represents the plasma membrane was selected for bleaching and monitoring recovery of fluorescence. The data on the diffusion coefficient (*D*) and mobile fraction (*M_f*) were calculated from quantitative FRAP experiments where just the bleached region was scanned to achieve improved temporal

resolution. FRAP experiments were performed with Gaussian spot photobleaching and line-scanning mode with a circular region of interest of 1- μm radius. Data representing the mean fluorescence intensity in the membrane region (obtained using Zeiss LSM 510 software, version 3.2) within the bleached spot were corrected for background and analyzed. For a two-dimensional diffusion model, FRAP data were fitted to determine the characteristic diffusion time (τ_d) (72),

$$F(t) = (F(\infty) - F(0))(\exp(-2\tau_d/t)(I_0(2\tau_d/t) + I_1(2\tau_d/t))) + F(0) \quad (\text{Eq. 1})$$

where $F(t)$ is the mean background-corrected and normalized fluorescence intensity at time t in the membrane region within the bleached spot, $F(\infty)$ is the recovered fluorescence at time $t \rightarrow \infty$, and $F(0)$ is the bleached fluorescence intensity at time $t \rightarrow 0$. I_0 and I_1 are modified Bessel functions. The effective two-dimensional diffusion coefficient (D) is determined from the equation (73),

$$D = \omega^2/2\tau_d \quad (\text{Eq. 2})$$

where ω is the radius of the bleached spot. The mobile fraction (M_f) is calculated according to the equation,

$$M_f = (F(\infty) - F(0))/(F(p) - F(0)) \quad (\text{Eq. 3})$$

where $F(p)$ is the mean background-corrected and normalized prebleach fluorescence intensity. Non-linear curve fitting of fluorescence recovery data to Equation 1 was carried out using GraphPad Prism software version 4.00 (La Jolla, CA).

Measurement of membrane dipole potential

Dipole potential measurements were carried out by a dual-wavelength ratiometric approach using the voltage-sensitive fluorescence probe di-8-ANEPPS (74–77). PM fractions (10 $\mu\text{g}/\text{ml}$) of *C. albicans* WT, NKKY101, and NKKY102 strains were incubated with the di-8-ANEPPS probe (1 nM) in the dark for 30 min at 25 °C. Steady-state fluorescence measurements were performed with an RF-5301PC spectrofluorophotometer (Shimadzu, Kyoto, Japan) using 1-cm path length quartz cuvettes at room temperature (~ 23 °C). Excitation and emission slits with a band pass of 5 nm were used for all measurements. Background intensities of samples were subtracted from each sample to cancel any contribution due to the solvent Raman peak. Fluorescence intensities were recorded at two excitation wavelengths (420 and 520 nm). The emission wavelength was fixed at 670 nm. The fluorescence ratio (R), defined as the ratio of fluorescence intensity at an excitation wavelength of 420 nm to that at 520 nm (emission at 670 nm in both cases), which is a measure of membrane dipole potential, was calculated (74). The choice of the emission wavelength (670 nm) at the red edge of the fluorescence spectrum has previously been shown to rule out membrane fluidity effects (78). Dipole potential (ψ_D) in mV was calculated from R using the linear relationship (74),

$$\psi_D = (R + 0.3)/(4.3 \times 10^{-3}) \quad (\text{Eq. 4})$$

Experiments were performed in triplicate, and results are shown as means \pm S.D. Student's t test was used to calculate statistical significance value.

Lipidome analysis

Lipid extraction was performed as described previously (71). Lipidome analysis was performed at the Kansas Lipidomics Research Center Analytical Laboratory, using an ESI source on a triple quadrupole mass spectrometer (ESI-MS/MS) (API 4000, Applied Biosystems) (71). Experiments were performed in quadruplet, and results are shown as means \pm S.E. A statistical significance value of 0.05 was employed using Student's t test.

Transcriptome analysis

Samples for transcriptome analysis were prepared as described previously (30). Microarray and data scanning was performed by Genotypic Technology Ltd. (Bangalore, India). The genes whose level varied ≥ 2 -fold between NKKY101 and WT were considered significantly affected genes. The transcription profile was analyzed using the Go-Slim mapper and was annotated on the basis of biological processes (79). Cytoscape version 3.4.0 software was used to create an interacting map of the top five up- and down-regulated categories (80). The microarrays used in the present study along with complete raw transcriptome data can be accessed from the NCBI Gene Expression Omnibus database under accession number GSE70340.

CK2 kinase activity assay

The recombinant protein His₆-Sic1 was expressed and purified from *E. coli* as reported previously (55). Briefly, His₆-Sic1 was purified on Ni²⁺-nitrilotriacetic acid beads, as described by the manufacturer (QIAexpressionist Handbook, Qiagen), and eluted with 100 mM imidazole. The protein concentration was measured by the Bradford method using the Bio-Rad protein assay kit.

C. albicans strains were grown in YPD medium until early exponential phase (0.2–0.3 OD/ml), and crude extract was prepared as described previously (81). The CK2 activity of crude protein extracts (0.35 μg) was tested using the purified recombinant protein His₆-Sic1 (7.5 μg) as a substrate in a reaction mix containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM MgCl₂, 0.1 mM ATP at 30 °C for the indicated times. Then CK2 phosphorylation on His₆-Sic1 was analyzed by SDS-PAGE, blotted, and probed with anti-Sic1-pSer-201 antibody (1:2000 dilution) and with anti-His probe antibody (1:1000 dilution; Santa Cruz Biotechnology) as a control (82). Densitometric analysis of three independent experiments was performed by using the ImageJ program.

Hog1 Western blots

Overnight cultures of *C. albicans* WT (SC5314), NKKY101, and NKKY102 strains were diluted to $A_{600} = 0.2$ and grown at 30 °C for 6 h. Cells were pelleted down and immediately frozen in liquid nitrogen. Cell extract was prepared as described previously (81), and 60 μg of total cell extract protein was separated by 8% PAGE and blotted. The level of phosphorylated

Cdr6/Roa1, a plasma membrane ABC transporter of C. albicans

Hog1 protein was detected using anti-dually phosphorylated p38 antibody (Cell Signaling Technology), and total Hog1 protein was detected with anti-Hog1p antibody (Y-215; Santa Cruz Biotechnology). Band intensities were quantified through Image Lab™ software (Bio-Rad), and Hog1 was used as a loading control.

Mouse survival and kidney fungal burden assay

All animal experiments performed in the absence of drug were executed at the University Hospital Center of Lausanne as described previously (30). Briefly, for all mouse experiments, female BALB/c mice (6 weeks old; Charles River France) were housed in ventilated cages with free access to food and water. Overnight secondary cultures grown in YEPD at 30 °C were washed twice and resuspended in 5 ml of PBS to the desired concentration. For survival and kidney fungal burden experiments in the absence of drug, groups of 10 mice were used. The mice were injected through the lateral tail vein with 250 μ l of a cell suspension containing 2×10^6 cells/ml for survival and 8×10^5 cells/ml for fungal burden experiments. The postinfection day of natural death or euthanasia of moribund animals was recorded for each mouse. Statistical analyses of the survival data were performed using the log-rank (Mantel-Cox) test. Concerning the fungal burden experiment at 3 days postinfection, the kidneys were recovered, and the cfu were determined as described previously (83). Statistical analyses of the differences between cfu values were performed using the Mann-Whitney test.

The kidney burden study in the presence of FLC was performed at the Public Health Research Institute (Rutgers University). For the kidney burden study in the presence of FLC with single-strain infections, groups of 10 female mice were used. On day 0, female BALB/c mice were challenged with suspensions of *C. albicans* strains (WT, NKKY101, and NKKY102) at 2×10^5 cells/ml, administered by tail vein injection. At 3 h after infection, mice were treated with FLC (20 mg/kg) via intraperitoneal injection, and these treatments were administered once daily for 3 days after the first dose. Three mice from each strain group were euthanized at 24, 48, and 72 h postinfection, and kidneys were harvested and enumerated for *C. albicans* burdens.

Ethical statement

All survival assay animal experiments were performed at the University Hospital Center of Lausanne with approval through the Institutional Animal Use Committee, Affaires Vétérinaires du Canton de Vaud, Switzerland (authorization number 1734.3), according to decree 18 of the federal law on animal protection. All animal drug treatment experiments were conducted at the Public Health Research Institute, Rutgers University. All animals were housed and handled according to the guidelines set forth by the institutional animal care and use committee. Animal protocols (protocol number D-15138-A1) were reviewed and approved by the institutional animal care and use committee of Rutgers University. The animal experiments were conducted in facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal

Care and were in full compliance with the United States Animal Welfare Act (Public Law 98-198).

Author contributions—N. K. K. and R. P. conceived of and designed the study. N. K. K. designed and performed selection experiments, drug-susceptibility assays, strain construction, R123 and BER transport assays, qRT-PCR, and Western blotting. R. P., A. C., N. K. K., and P. S. designed and N. K. K. and P. S. performed the FRAP experiment to measure the PM fluidity. B. D. E. and T. C. W. designed and performed the azole accumulation experiment. P. C. designed and performed CK2 kinase activity assays. R. P., N. K. K., and A. S. designed and performed the lipidomic analysis. N. C. designed and performed the *C. albicans* mouse study in the presence of azole. A. T. C. and D. S. designed and performed the virulence and kidney burden assay in the absence of drug. N. K. K. and M. G. designed and analyzed the transcriptome profile. M. C. and C. E. constructed the CDR6/ROA1 overexpression plasmid. A. K. M., R. P., and N. K. K. designed the Hog1 activity analysis, and N. K. K. performed the experiment. N. A. G. provided reagents for the rebuttal experiment. R. P., N. K. K., and M. G. wrote the paper with input from the other authors. All authors read and approved the final paper.

Acknowledgments—We acknowledge Dr. Sunil Shetty for valuable discussions and suggestions during the work. We acknowledge AIRF, JNU, for providing instrumental support and Ashok Kumar Sahu and Tripti Panwar for confocal microscopy. We thank Amarchand Kumar for help with ultracentrifugation. We thank Kauschal Kumar Mahto, Mohd. Wasi, and Debasree Kundu for help during lipid preparation, bioinformatic analysis, and Hog1 Western blotting, respectively. The help of Dr. Rupinder Kaur in providing the facility for *C. albicans* strain growth during the FRAP experiment is greatly appreciated.

References

1. Pfaller, M. A., and Diekema, D. J. (2007) Epidemiology of invasive candidiasis: a persistent public health problem. *Clin. Microbiol. Rev.* **20**, 133–163 [CrossRef Medline](#)
2. Zaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., and Feudtner, C. (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. *Clin. Infect. Dis.* **41**, 1232–1239 [CrossRef Medline](#)
3. Cowen, L. E. (2008) The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. *Nat. Rev. Microbiol.* **6**, 187–198 [CrossRef Medline](#)
4. Sanglard, D. (2016) Emerging threats in antifungal-resistant fungal pathogens. *Front. Med.* **3**, 11 [CrossRef Medline](#)
5. Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., and Bille, J. (1995) Mechanisms of resistance to azole antifungal agents in *Candida albicans* isolates from AIDS patients involve specific multidrug transporters. *Antimicrob. Agents Chemother.* **39**, 2378–2386 [CrossRef Medline](#)
6. White, T. C. (1997) Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in *Candida albicans* isolates from a patient infected with human immunodeficiency virus. *Antimicrob. Agents Chemother.* **41**, 1482–1487 [Medline](#)
7. Lyons, C. N., and White, T. C. (2000) Transcriptional analyses of antifungal drug resistance in *Candida albicans*. *Antimicrob. Agents Chemother.* **44**, 2296–2303 [CrossRef Medline](#)
8. Kohli, A., Smriti, Mukhopadhyay, K., Rattan, A., and Prasad, R. (2002) *In vitro* low-level resistance to azoles in *Candida albicans* is associated with changes in membrane lipid fluidity and asymmetry. *Antimicrob. Agents Chemother.* **46**, 1046–1052 [CrossRef Medline](#)
9. Mukhopadhyay, K., Kohli, A., and Prasad, R. (2002) Drug susceptibilities of yeast cells are affected by membrane lipid composition drug suscepti-

- bilities of yeast cells are affected by membrane lipid composition. *Antimicrob. Agents Chemother.* **46**, 3695–3705 [CrossRef Medline](#)
10. Prasad, T., Chandra, A., Mukhopadhyay, C. K., and Prasad, R. (2006) Unexpected link between iron and drug resistance of *Candida* spp.: iron depletion enhances membrane fluidity and drug diffusion, leading to drug-susceptible cells. *Antimicrob. Agents Chemother.* **50**, 3597–3606 [CrossRef Medline](#)
 11. Berchtold, D., Piccolis, M., Chiaruttini, N., Riezman, I., Riezman, H., Roux, A., Walther, T. C., and Loewith, R. (2012) Plasma membrane stress induces relocalization of Slm proteins and activation of TORC2 to promote sphingolipid synthesis. *Nat. Cell Biol.* **14**, 542–547 [CrossRef Medline](#)
 12. Pike, L. J. (2006) Rafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell Function. *J. Lipid Res.* **47**, 1597–1598 [CrossRef Medline](#)
 13. Mollinedo, F. (2012) Lipid raft involvement in yeast cell growth and death. *Front. Oncol.* **2**, 140 [Medline](#)
 14. Rella, A., Farnoud, A. M., and Del Poeta, M. (2016) Plasma membrane lipids and their role in fungal virulence. *Prog. Lipid Res.* **61**, 63–72 [CrossRef Medline](#)
 15. Pasrija, R., Panwar, S. L., and Prasad, R. (2008) Multidrug transporters CaCdr1p and CaMdr1p of *Candida albicans* display different lipid specificities: both ergosterol and sphingolipids are essential for targeting of CaCdr1p to membrane rafts. *Antimicrob. Agents Chemother.* **52**, 694–704 [CrossRef Medline](#)
 16. Mukhopadhyay, K., Prasad, T., Saini, P., Pucadyil, T. J., Chattopadhyay, A., and Prasad, R. (2004) Membrane sphingolipid-ergosterol interactions are important determinants of multidrug resistance in *Candida albicans*. *Antimicrob. Agents Chemother.* **48**, 1778–1787 [CrossRef Medline](#)
 17. Taipale, M., Jarosz, D. F., and Lindquist, S. (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. *Nat. Rev. Mol. Cell Biol.* **11**, 515–528 [CrossRef Medline](#)
 18. Sanchez-Casalogue, M. E., Lee, J., Diamond, A., Shuldiner, S., Moir, R. D., and Willis, I. M. (2015) Differential phosphorylation of a regulatory subunit of protein kinase CK2 by target of rapamycin complex 1 signaling and the Cdc-like kinase Kns1. *J. Biol. Chem.* **290**, 7221–7233 [CrossRef Medline](#)
 19. Lee, J., Moir, R. D., McIntosh, K. B., and Willis, I. M. (2012) TOR signaling regulates ribosome and tRNA synthesis via LAMMER/Clk and GSK-3 family kinases. *Mol. Cell* **45**, 836–843 [CrossRef Medline](#)
 20. Mollapour, M., Tsutsumi, S., Truman, A. W., Xu, W., Vaughan, C. K., Beebe, K., Konstantinova, A., Vourganti, S., Panaretou, B., Piper, P. W., Trepel, J. B., Prodromou, C., Pearl, L. H., and Neckers, L. (2011) Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. *Mol. Cell* **41**, 672–681 [CrossRef Medline](#)
 21. Diezmann, S., Michaut, M., Shapiro, R. S., Bader, G. D., and Cowen, L. E. (2012) Mapping the Hsp90 genetic interaction network in *Candida albicans* reveals environmental contingency and rewired circuitry. *PLoS Genet.* **8**, e1002562 [CrossRef Medline](#)
 22. Shekhar-Guturja, T., Gunaherath, G. M. K. B., Wijeratne, E. M. K., Lambert, J.-P., Averette, A. F., Lee, S. C., Kim, T., Bahn, Y.-S., Tripodi, F., Ammar, R., Döhl, K., Niewola-Staszowska, K., Schmitt, L., Loewith, R. J., Roth, F. P., *et al.* (2016) Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. *Nat. Chem. Biol.* **12**, 867–875 [CrossRef Medline](#)
 23. Liu, T. T., Znaidi, S., Barker, K. S., Xu, L., Homayouni, R., Saidane, S., Morschhäuser, J., Nantel, A., Raymond, M., and Rogers, P. D. (2007) Genome-wide expression and location analyses of the *Candida albicans* Tac1p regulon. *Eukaryot. Cell* **6**, 2122–2138 [CrossRef Medline](#)
 24. Dhamgaye, S., Bernard, M., Lelandais, G., Sismeyro, O., Lemoine, S., Coppée, J.-Y., Le Crom, S., Prasad, R., and Devaux, F. (2012) RNA sequencing revealed novel actors of the acquisition of drug resistance in *Candida albicans*. *BMC Genomics* **13**, 396 [CrossRef Medline](#)
 25. Jiang, L., Xu, D., Chen, Z., Cao, Y., Gao, P., and Jiang, Y. (2016) The putative ABC transporter encoded by the orf19.4531 plays a role in the sensitivity of *Candida albicans* cells to azole antifungal drugs. *FEMS Yeast Res.* **16**, fow024 [CrossRef Medline](#)
 26. Prasad, R., Banerjee, A., Khandelwal, N. K., and Dhamgaye, S. (2015) The ABCs of *Candida albicans* multidrug transporter Cdr1. *Eukaryot. Cell* **14**, 1154–1164 [CrossRef Medline](#)
 27. Smriti, Krishnamurthy, S., Dixit, B. L., Gupta, C. M., Milewski, S., and Prasad, R. (2002) ABC transporters CdrLp, Cdr2p and Cdr3p of a human pathogen *Candida albicans* are general phospholipid translocators. *Yeast* **19**, 303–318 [CrossRef Medline](#)
 28. Abe, F., and Hiraki, T. (2009) Mechanistic role of ergosterol in membrane rigidity and cycloheximide resistance in *Saccharomyces cerevisiae*. *Biochim. Biophys. Acta.* **1788**, 743–752 [CrossRef Medline](#)
 29. Lamping, E., Monk, B. C., Niimi, K., Holmes, A. R., Tsao, S., Tanabe, K., Niimi, M., Uehara, Y., and Cannon, R. D. (2007) Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in *Saccharomyces cerevisiae*. *Eukaryot. Cell* **6**, 1150–1165 [CrossRef Medline](#)
 30. Khandelwal, N. K., Kaemmer, P., Forster, T. M., Singh, A., Coste, A. T., Andes, D. R., Hube, B., Sanglard, D., Chauhan, N., Kaur, R., d'Enfert, C., Mondal, A. K., and Prasad, R. (2016) Pleiotropic effects of the vacuolar ABC transporter MLT1 of *Candida albicans* on cell function and virulence. *Biochem. J.* **473**, 1537–1552 [CrossRef Medline](#)
 31. Rawal, M. K., Khan, M. F., Kapoor, K., Goyal, N., Sen, S., Saxena, A. K., Lynn, A. M., Tyndall, J. D. A., Monk, B. C., Cannon, R. D., Komath, S. S., and Prasad, R. (2013) Insight into pleiotropic drug resistance ATP-binding cassette pump drug transport through mutagenesis of Cdr1p transmembrane domains. *J. Biol. Chem.* **288**, 24480–24493 [CrossRef Medline](#)
 32. Reuss, O., Vik, A., Kolter, R., and Morschhäuser, J. (2004) The SAT1 flipper, an optimized tool for gene disruption in *Candida albicans*. *Gene* **341**, 119–127 [CrossRef Medline](#)
 33. Mansfield, B. E., Oltean, H. N., Oliver, B. G., Hoot, S. J., Leyde, S. E., and White, T. C. (2010) Azole drugs are imported by facilitated diffusion in *Candida albicans* and other pathogenic fungi. *PLoS Pathog.* **6**, e1001126 [CrossRef Medline](#)
 34. Prasad, R., Khandelwal, N. K., and Banerjee, A. (2016) Yeast ABC transporters in lipid trafficking. *Fungal Genet. Biol.* **93**, 25–34 [CrossRef Medline](#)
 35. Tarling, E. J., de Aguiar Vallim, T. Q., and Edwards, P. (2013) A role of ABC transporters in lipid transport and human disease. *Trends Endocrinol. Metab.* **24**, 342–350 [CrossRef Medline](#)
 36. Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., and Perlin, D. S. (2014) Mechanisms of antifungal drug resistance. *Cold Spring Harb. Perspect. Med.* [CrossRef Medline](#)
 37. Kododová, M., and Sychrová, H. (2015) Changes in the sterol composition of the plasma membrane affect membrane potential, salt tolerance and the activity of multidrug resistance pumps in *Saccharomyces cerevisiae*. *PLoS One* **10**, e0139306 [CrossRef Medline](#)
 38. Dawaliby, R., Trubbia, C., Delporte, C., Noyon, C., Ruysschaert, J.-M., Van Antwerpen, P., and Govaerts, C. (2016) Phosphatidylethanolamine is a key regulator of membrane fluidity in eukaryotic cells. *J. Biol. Chem.* **291**, 3658–3667 [CrossRef Medline](#)
 39. Loewith, R., and Hall, M. N. (2011) Target of rapamycin (TOR) in nutrient signaling and growth control. *Genetics* **189**, 1177–1201 [CrossRef Medline](#)
 40. Heitman, J., Movva, N. R., and Hall, M. N. (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. *Science* **253**, 905–909 [CrossRef Medline](#)
 41. Croons, V., Martinet, W., Herman, A. G., Timmermans, J.-P., and De Meyer, G. R. Y. (2009) The protein synthesis inhibitor anisomycin induces macrophage apoptosis in rabbit atherosclerotic plaques through p38 mitogen-activated protein kinase. *J. Pharmacol. Exp. Ther.* **329**, 856–864 [CrossRef Medline](#)
 42. Grollman, A. P. (1967) Inhibitors of protein biosynthesis. II. Mode of action of anisomycin. *J. Biol. Chem.* **242**, 3226–3233 [Medline](#)
 43. Rao, S. S., and Grollman, A. P. (1967) Cycloheximide resistance in yeast: a property of the 60s ribosomal subunit. *Biochem. Biophys. Res. Commun.* **29**, 696–704 [CrossRef Medline](#)
 44. Sweeney, R., Yao, C. H., and Yao, M. C. (1991) A mutation in the large subunit ribosomal RNA gene of *Tetrahymena* confers anisomycin resistance and cold sensitivity. *Genetics* **127**, 327–334 [Medline](#)
 45. Liu, M., Huang, C., Polu, S. R., Schneiter, R., and Chang, A. (2012) Regulation of sphingolipid synthesis through Orm1 and Orm2 in yeast. *J. Cell Sci.* **125**, 2428–2435 [CrossRef Medline](#)

Cdr6/Roa1, a plasma membrane ABC transporter of C. albicans

46. Shimobayashi, M., Oppliger, W., Moes, S., Jenö, P., and Hall, M. N. (2013) TORC1-regulated protein kinase Npr1 phosphorylates Orm to stimulate complex sphingolipid synthesis. *Mol. Biol. Cell* **24**, 870–881 [CrossRef Medline](#)
47. Breslow, D. K., Collins, S. R., Bodenmiller, B., Aebersold, R., Simons, K., Shevchenko, A., Ejsing, C. S., and Weissman, J. S. (2010) Orm family proteins mediate sphingolipid homeostasis. *Nature* **463**, 1048–1053 [CrossRef Medline](#)
48. Han, S., Lone, M. A., Schneiter, R., and Chang, A. (2010) Orm1 and Orm2 are conserved endoplasmic reticulum membrane proteins regulating lipid homeostasis and protein quality control. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 5851–5856 [CrossRef Medline](#)
49. Delgado, A., Casas, J., Llebaria, A., Abad, J. L., and Fabrias, G. (2006) Inhibitors of sphingolipid metabolism enzymes. *Biochim. Biophys. Acta* **1758**, 1957–1977 [CrossRef Medline](#)
50. Cowen, L. E., and Lindquist, S. (2005) Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. *Science* **309**, 2185–2189 [CrossRef Medline](#)
51. Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D., and Cowen, L. E. (2011) Hsp90 governs dispersion and drug resistance of fungal biofilms. *PLoS Pathog.* **7**, e1002257 [CrossRef Medline](#)
52. Sanglard, D., Ischer, F., Marchetti, O., Entenza, J., and Bille, J. (2003) Calcineurin A of *Candida albicans*: involvement in antifungal tolerance, cell morphogenesis and virulence. *Mol. Microbiol.* **48**, 959–976 [CrossRef Medline](#)
53. Imai, J., and Yahara, I. (2000) Role of HSP90 in salt stress tolerance via stabilization and regulation of calcineurin. *Mol. Cell Biol.* **20**, 9262–9270 [CrossRef Medline](#)
54. Kumar, R., Musiyenko, A., and Barik, S. (2005) *Plasmodium falciparum* calcineurin and its association with heat shock protein 90: mechanisms for the antimalarial activity of cyclosporin A and synergism with geldanamycin. *Mol. Biochem. Parasitol.* **141**, 29–37 [CrossRef Medline](#)
55. Coccetti, P., Rossi, R. L., Sternieri, F., Porro, D., Russo, G. L., di Fonzo, A., Magni, F., Vanoni, M., and Alberghina, L. (2004) Mutations of the CK2 phosphorylation site of Sic1 affect cell size and S-Cdk kinase activity in *Saccharomyces cerevisiae*. *Mol. Microbiol.* **51**, 447–460 [CrossRef Medline](#)
56. Hawle, P., Horst, D., Bebelman, J. P., Yang, X. X., Siderius, M., and van der Vies, S. M. (2007) Cdc37p is required for stress-induced high-osmolarity glycerol and protein kinase C mitogen-activated protein kinase pathway functionality by interaction with Hog1p and Slf2p (Mpk1p). *Eukaryot. Cell* **6**, 521–532 [CrossRef Medline](#)
57. Leach, M. D., Budge, S., Walker, L., Munro, C., Cowen, L. E., and Brown, A. J. P. (2012) Hsp90 orchestrates transcriptional regulation by Hsf1 and cell wall remodelling by MAPK signalling during thermal adaptation in a pathogenic yeast. *PLoS Pathog.* **8**, e1003069 [CrossRef Medline](#)
58. Duina, A. A., Kalton, H. M., and Gaber, R. F. (1998) Requirement for Hsp90 and a CyP-40-type cyclophilin in negative regulation of the heat shock response. *J. Biol. Chem.* **273**, 18974–18978 [CrossRef Medline](#)
59. Nicholls, S., Leach, M. D., Priest, C. L., and Brown, A. J. P. (2009) Role of the heat shock transcription factor, Hsf1, in a major fungal pathogen that is obligately associated with warm-blooded animals. *Mol. Microbiol.* **74**, 844–861 [CrossRef Medline](#)
60. Cowen, L. E. (2013) The fungal Achilles' heel: targeting Hsp90 to cripple fungal pathogens. *Curr. Opin. Microbiol.* **16**, 377–384 [CrossRef Medline](#)
61. Shah, A. H., Singh, A., Dhamgaye, S., Chauhan, N., Vandeputte, P., Suneetha, K. J., Kaur, R., Mukherjee, P. K., Chandra, J., Ghannoum, M. A., Sanglard, D., Goswami, S. K., and Prasad, R. (2014) Novel role of a family of major facilitator transporters in biofilm development and virulence of *Candida albicans*. *Biochem. J.* **460**, 223–235 [CrossRef Medline](#)
62. De Virgilio, C., and Loewith, R. (2006) The TOR signalling network from yeast to man. *Int. J. Biochem. Cell Biol.* **38**, 1476–1481 [CrossRef Medline](#)
63. Cruz, M. C., Goldstein, A. L., Blankenship, J., Del Poeta, M., Perfect, J. R., McCusker, J. H., Bennani, Y. L., Cardenas, M. E., and Heitman, J. (2001) Rapamycin and less immunosuppressive analogs are toxic to *Candida albicans* and *Cryptococcus neoformans* via FKBP12-dependent inhibition of TOR. *Antimicrob. Agents Chemother.* **45**, 3162–3170 [CrossRef Medline](#)
64. Trepel, J., Mollapour, M., Giaccone, G., and Neckers, L. (2010) Targeting the dynamic HSP90 complex in cancer. *Nat. Rev. Cancer* **10**, 537–549 [CrossRef Medline](#)
65. Bastidas, R. J., Heitman, J., and Cardenas, M. E. (2009) The protein kinase Tor1 regulates adhesin gene expression in *Candida albicans*. *PLoS Pathog.* **5**, e1000294 [CrossRef Medline](#)
66. Cabral, V., Chauvel, M., Firon, A., Legrand, M., Nesseir, A., Bachellier-Bassi, S., Chaudhari, Y., Munro, C. A., and d'Enfert, C. (2012) Modular gene over-expression strategies for *Candida albicans*. *Methods Mol. Biol.* **845**, 227–244 [CrossRef Medline](#)
67. Murad, A. M., Lee, P. R., Broadbent, I. D., Barelle, C. J., and Brown, A. J. (2000) CIP10, an efficient and convenient integrating vector for *Candida albicans*. *Yeast* **16**, 325–327 [CrossRef Medline](#)
68. Tamura, K., Stecher, G., Peterson, D., Filipski, A., and Kumar, S. (2013) MEGA6: molecular evolutionary genetics analysis version 6.0. *Mol. Biol. Evol.* **30**, 2725–2729 [CrossRef Medline](#)
69. Bernsel, A., Viklund, H., Hennerdal, A., and Elofsson, A. (2009) TOPCONS: consensus prediction of membrane protein topology. *Nucleic Acids Res.* **37**, W465–W468 [CrossRef Medline](#)
70. Shukla, S., Saini, P., Smriti, Jha, S., Ambudkar, S. V., Prasad, R., and Ambudkar, S. (2003) Functional characterization of *Candida albicans* ABC transporter Cdr1p. *Eukaryot. Cell* **2**, 1361–1375 [CrossRef Medline](#)
71. Mahto, K. K., Singh, A., Khandelwal, N. K., Bhardwaj, N., Jha, J., and Prasad, R. (2014) An assessment of growth media enrichment on lipid metabolome and the concurrent phenotypic properties of *Candida albicans*. *PLoS One* **9**, e113664, [CrossRef Medline](#)
72. Pucadyil, T. J., Kalipatnapu, S., Harikumar, K. G., Rangaraj, N., Karnik, S. S., and Chattopadhyay, A. (2004) G-protein-dependent cell surface dynamics of the human serotonin1A receptor tagged to yellow fluorescent protein. *Biochemistry* **43**, 15852–15862 [CrossRef Medline](#)
73. Koppel, D. E., Sheetz, M. P., and Schindler, M. (1980) Lateral diffusion in biological membranes. A normal-mode analysis of diffusion on a spherical surface. *Biophys. J.* **30**, 187–192 [CrossRef Medline](#)
74. Starke-Peterkovic, T., Turner, N., Vitha, M. F., Waller, M. P., Hibbs, D. E., and Clarke, R. J. (2006) Cholesterol effect on the dipole potential of lipid membranes. *Biophys. J.* **90**, 4060–4070 [CrossRef Medline](#)
75. Gross, E., Bedlack, R. S., Jr., and Loew, L. M. (1994) Dual-wavelength ratiometric fluorescence measurement of the membrane dipole potential. *Biophys. J.* **67**, 208–216 [CrossRef Medline](#)
76. Haldar, S., Kanaparthi, R. K., Samanta, A., and Chattopadhyay, A. (2012) Differential effect of cholesterol and its biosynthetic precursors on membrane dipole potential. *Biophys. J.* **102**, 1561–1569 [CrossRef Medline](#)
77. Starke-Peterkovic, T., Turner, N., Else, P. L., and Clarke, R. J. (2005) Electric field strength of membrane lipids from vertebrate species: membrane lipid composition and Na⁺-K⁺-ATPase molecular activity. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **288**, R663–R670 [Medline](#)
78. Clarke, R. J., and Kane, D. J. (1997) Optical detection of membrane dipole potential: avoidance of fluidity and dye-induced effects. *Biochim. Biophys. Acta.* **1323**, 223–239 [CrossRef Medline](#)
79. Boyle, E. I., Weng, S., Gollub, J., Jin, H., Botstein, D., Cherry, J. M., and Sherlock, G. (2004) GO::TermFinder: open source software for accessing gene ontology information and finding significantly enriched gene ontology terms associated with a list of genes. *Bioinformatics* **20**, 3710–3715 [CrossRef Medline](#)
80. Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., and Ideker, T. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* **13**, 2498–2504 [CrossRef Medline](#)
81. Sharma, P., Meena, N., Aggarwal, M., and Mondal, A. K. (2005) *Debaryomyces hansenii*, a highly osmo-tolerant and halo-tolerant yeast, maintains activated Dhog1p in the cytoplasm during its growth under severe osmotic stress. *Curr. Genet.* **48**, 162–170 [CrossRef Medline](#)
82. Tripodi, F., Cirulli, C., Reghellin, V., Marin, O., Brambilla, L., Schiappelli, M. P., Porro, D., Vanoni, M., Alberghina, L., and Coccetti, P. (2010) CK2 activity is modulated by growth rate in *Saccharomyces cerevisiae*. *Biochem. Biophys. Res. Commun.* **398**, 44–50 [CrossRef Medline](#)
83. Vandeputte, P., Ischer, F., Sanglard, D., and Coste, A. T. (2011) *In vivo* systematic analysis of *Candida albicans* Zn2-Cys6 transcription factors mutants for mice organ colonization. *PLoS One* **6**, e26962 [CrossRef Medline](#)